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ABSTRACT 
 
Eicosanoids are signaling molecules formed from the oxidation of -3 and -6 fatty acids. 
CYP2J2 and CYP5A1 are two key enzymes involved in the formation of eicosanoids. CYP2J2 
is a classical P450 which requires transfer of electrons from its obligate redox partner, 
cytochrome P450 reductase (CPR). Here the triphasic kinetics of the potentially rate-limiting 
first electron transfer from CPR to CYP2J2 are reported. These rates are similar to previously 
reported rates of other CYPs and show differences with CYP2J2 in the presence of the 
substrates arachidonic acid (AA) and ebastine. When CYP2J2 and CPR were not allowed to 
pre-incubate, use of a truncated CYP2J2 without the hydrophobic N-terminus caused a 200-
fold decrease in the kinetics of electron transfer. In a step towards being able to gain structural 
data for CYP2J2, the protein was mutated at its surface to increase solubility. Individual 
mutations of I236D and F239H altered the metabolism of AA and/or ebastine, however there 
was complementation in the double mutant such that substrate metabolism was near that of 
wild type levels. Further investigation into the reaction cycle of CYP2J2 involved mutation of 
the highly conserved I-helix residue T315 near the heme. This mutation not only altered the 
rate of AA metabolism, but also altered the ratio of hydroxylation to epoxidation products. A 
similar study was carried out with the non-classical CYP5A1, which isomerizes prostaglandin 
H2 (PGH2) to thromboxane A2 (TXA2) rather than being reduced prior to hydroxylation or 
epoxidation of a substrate. This CYP has I346 in the position normally occupied by highly 
conserved I-helix threonine, so in this study the mutants I346T and I346S were created. Each 
of these hydroxyl-containing mutants showed increased isomerization of PGH2. In addition, 
I346T appeared to have a more constrained active site than I346S based on the ability to bind 
substrate analogs. A previously unknown protein-protein interaction between CYP5A1 and 
CPR was also shown via a direct titration and by monitoring the ability of CPR to produce 
H2O2 in the presence of CYP5A1. These studies of protein-protein interactions and of a key 
active site residue in both CYP2J2 and CYP5A1 complement each other. 
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CHAPTER 1: INTRODUCTION 
 
Overview of P450s 
 
The cytochromes P450 are a superfamily of heme-containing enzymes most often associated 
with monooxygenase reactions. This class of enzymes was first discovered in the 1950s for their 
ability to oxidize xenobiotic compounds in the liver, an essential step in the elimination of these 
compounds. The name “P450” comes from the characteristic absorbance peak at 450 nm of the 
ferrous-CO enzyme following chemical reduction with dithionite and mixing with carbon 
monoxide in solution (1). Another key role of P450 enzymes is the ability of particular isozymes 
to carry out specific reactions, often hydroxylations and epoxygenations, in the biosynthesis of 
naturally occurring molecules such as steroid hormones (2). 
 
Cytochromes P450 are ubiquitous throughout nature as they are found in all kingdoms of life, 
which includes a wide diversity of organisms such as bacteria, archaebacteria, fungi, plants, and 
animals. As sequencing of genomes is becoming more feasible, the number of known P450 
sequences has increased to over 21,000 as of 2013 (3). A comparison of the tertiary structure of 
P450 enzymes shows a highly conserved backbone of 13 alpha helices and 7 beta sheets in the 
heme-containing alpha domain and 3 alpha helices and 7 beta sheets in the beta domain (Fig 1.1) 
(2, 4). Nomenclature, however, is based on primary sequence homology. Proteins with 40% 
sequence identity are grouped into numbered families (e.g., CYP1 or CYP2). There are 57 CYPs 
in 17 families for human and over 700 families in all organisms (3). Within a family, members 
that share 55% sequence identity are grouped into a lettered subfamily, such as CYP1A or 
CYP1B. Each subfamily member is given a further number designation, such as CYP1A1 or 
CYP1A2. The final level in the scheme of naming these enzymes is the variant, which is 
appended to the name with a designation such as v1, v2, v3, etc. To be considered the same 
variant there must be at least 97% sequence identity (3). Finally, polymorphisms that vary at 
individual positions can be designated as *1, *2, *3, etc. at the end of the name (Fig 1.2) (5). 
 
As the number of available P450 sequences increases through genome sequencing, more 
information can be gained from primary sequence homology and from 3-D structural alignments. 
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These comparisons can be made within a family of P450 enzymes, for example the 17 members 
of family 2. Alternatively, a comparison can be made among orthologous enzymes found in 
closely related organisms. In conjunction with information about substrate specificity, one can 
gain insights into the potential roles of various amino acids in the protein. Progress is still being 
made to predict the capabilities of novel P450 enzymes in silico based on their primary sequence.  
 
P450 reaction cycle 
 
Almost all known P450 enzymes catalyze reactions, often monooxygenation, by progressing 
through a reaction cycle that has been generally accepted since the 1970s (6). The beginning of 
the cycle is considered to be the resting state in which the substrate-free heme Fe of the P450 is 
ligated on the proximal side to a highly conserved cysteine residue and on the distal side is 
bound to a water molecule, thus resulting in a six-coordinate, low-spin (S=1/2) state. 
Traditionally, the second step is considered to be the point at which substrate is bound and the 
third step is the reduction from Fe(III) to Fe(II) via external electron transfer. In the substrate-
binding step, the ligand enters the binding pocket and positions itself in close proximity to the 
heme. When the water is displaced by substrate the Fe will be in a high-spin (S=5/2) state, which 
can be detected by measuring spectral shifts. Substrates will displace the water found at the heme 
with various degrees of efficiency. This high-spin state can result in a higher reduction potential 
of the heme. The traditional third step of the cycle, the first electron transfer, may actually occur 
prior to the second step. In this step an electron reduces the heme from an Fe(III) to an Fe(II) 
state following transfer from an obligate redox partner, which for CYPs studied in this 
dissertation is cytochrome P450 reductase (CPR). The original source of the electrons is NADH 
or NADPH (Equation 1.1), which transfers electrons to the FAD domain and then to the FMN 
domain of CPR. The rate at which these electrons are transferred from CPR to CYP depends on 
protein-protein interactions and has the potential to be a rate-limiting step of the pathway (7). 
The increase in reduction potential caused by the binding of substrate may be correlated to the 
rate of electron transfer. The following step is the binding of molecular oxygen to Fe(II), thus 
resulting in the ferric superoxide intermediate, Fe(III)-OO
-
. It is also at this step that under 
anaerobic conditions CO can be bound experimentally to Fe(II) to give rise to the characteristic 
peak at 450 nm. The intermediates in the cycle that follow this step are less stable. Next, a 
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second electron must be transferred from CPR or another redox partner such as cytochrome b5 
(7). This results in a ferric-peroxo intermediate, Fe(III)-OO
(2-)
. Following this the first of two 
protons is transferred most likely through a specific channel near the heme (8), resulting in the 
ferric-hydroperoxo intermediate, Fe(III)-OOH
(-)
. It is thought that for enzymes such as CYP2J2 it 
is this intermediate that initiates most epoxidation reactions and some hydroxylation reactions 
(9). Finally, a second proton transfer through a similar pathway results in a ferryl-oxo species, 
Fe(IV)-O, also known as “Compound I”. It is thought that for enzymes such as CYP2J2 it is this 
intermediate that initiates most hydroxylation reactions and some epoxidation reactions (9). The 
P450 cycle is usually not 100% efficient; i.e., there is “shunting” of intermediates to non-
productive pathways prior to reaction with a substrate. This shunting can lead to reversion to a 
ferric heme in three major ways: (1) the ferric superoxide intermediate can release superoxide via 
the autooxidation shunt, (2) the ferric-hydroperoxo intermediate can react with a proton and 
instead of forming Compound I can form hydrogen peroxide (H2O2) via the peroxide shunt, and 
(3) Compound I can react with two protons and two electrons rather than substrate in order to 
form a water molecule via the oxidase shunt (Fig 1.3) (10). 
 
NAD(P)H + H
+
 + RH + O2  NAD(P)
+
 + ROH + H2O   (Equation 1.1) 
 
CYP2J2 
 
CYP2J2 is expressed in liver, and it was discovered from a liver cDNA library in the mid-1990s 
(11). Today, CYP2J2 is most well-known for being highly expressed in the vascular endothelial 
cells of the heart (12). Along with other family 2 CYPs CYP2C8 and CYP2C9, CYP2J2 is 
responsible for the production of important eicosanoids, namely epoxyeicosatrienoic acids 
(EETs). The primary substrate for the formation of these and other eicosanoids is arachidonic 
acid (AA), although CYP2J2 can use other -3 and -6 fatty acids (13, 14). 
 
When CYP2J2 reacts with AA the primary reaction is epoxidation of one of its four double 
bonds. The four possible regioisomers that are formed are 14,15-EETs, 11,12-EETs, 8,9-EETs, 
and 5,6-EETs, with the numbering system indicating the carbon number starting at the carboxyl 
group of AA. Each of these regioisomers can be further subdivided into two possible 
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stereoisomers, for example 14,15-EETs may be either 14R,15S-EET or 14S,15R-EET (12, 13). 
The proportions of these eight possible epoxidation products differs greatly among enzymes such 
as CYP2J2, CYP2C8, and CYP2C9, and may even differ based on conditions surrounding each 
enzyme. This is important because each of these possible products has different levels of 
effectiveness toward regulating various biological functions. The level of EETs in a particular 
tissue is based not only on their rate of production but also on their rate of conversion to the less 
active dihydroxyeicosatrienoic acids (DHETs) by soluble epoxide hydrolases (sEHs) (15). 
 
Human CYP2J2 can also hydroxylate AA to form hydroxyeicosatetraenoic acids (HETEs) -19-
HETEs and 20-HETEs. Besides the ratios within the EETs and HETEs, the EETs/HETEs ratio is 
also important physiologically (16). This ratio can vary among the CYP2J2 enzymes of various 
species due to small differences in the enzyme sequences. For example, sheep CYP2J2 differs 
from that of human in that it produces fewer EETs and more HETEs, including 18-HETEs (14, 
17). Some other species have multiple isoforms in the CYP2J subfamily, and unlike human 
CYP2J2 they can sometimes hydroxylate AA at one of the double bonds thus forming products 
such as 5-HETE, 8-HETE, 11-HETE, 12-HETE, and 15-HETE (Fig 1.4) (14). 
 
CYP2J2 also metabolizes other endogenous substrates include conversion of eicosapentaenoic 
acid (EPA) to epoxyeicosatetraenoic acids (EEQs) and of docosahexaenoic acid (DHA) to 
epoxydocosapentaenoic acids (EDPs). The rate of these reactions is greater than the conversion 
of AA to EETs, in part due to the ease of reaction of the more terminal -3 bonds of EPA and 
DHA versus the -6 bond AA. The presence of the -3 bond also makes hydroxylation much 
less likely. In addition, human CYP2J2 also has the capability to do primarily epoxidation 
reactions with linoleic acid (LA) (14). 
 
CYP2J2 is the most highly expressed P450 in the myocardium. (11, 18). One of the cell types in 
the heart that expresses CYP2J2 is the muscle cell, or the myocyte. Intracellular EETs can affect 
various ion transporters to influence the important levels of Ca
2+,
 Na
+
, and K
+
 (19-23). These 
effects vary based on the type of EET regioisomer. 
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Endothelial cells in the heart and throughout the body also express CYP2J2, which affects a 
variety of biological processes (Fig 1.5) (12). These cells release EETs that act in paracrine and 
autocrine fashion upon vascular smooth muscle cells, thus causing vasodilation (24-27). When 
vasodilation is increased in the kidney due to EETs from CYP2J2 and other CYPs it can cause 
blood pressure to decrease due to a drop in blood sodium levels (28). 
 
CYP2J2 also plays a role in heart disease through the inhibition of atherosclerosis. The EETs 
released by endothelial cells in blood vessels can inhibit the ability of platelets to aggregate. One 
mechanism for this is by lowering the ability of the platelets to produce thromboxane A2 (TXA2), 
a molecule that promotes platelet aggregation (29). A second mechanism is that EETs promote a 
cascade of events in platelets that eventually lessen their adhesive properties (30). 
 
Another way that CYP2J2 can promote heart health is through its anti-inflammatory properties. 
Inflammation has a negative effect by promoting heart disease. Higher levels of EETs from 
CYP2J2 leads to lower levels of the cytokine TNF- (31). In addition, EETs lead to lower levels 
of the transcription factor NF-B, which can promote a number of inflammatory responses (31). 
CYP2J2 is also less inflammatory than other CYPs, such as CYP2C9, because of the release of a 
relatively low level of reactive oxygen species from CYP2J2 during oxygenation of fatty acids as 
compared to other CYPs (32). 
 
CYP5A1 
 
CYP5A1 is a non-classical P450 as it does not add an oxygen to its substrate via hydroxylation 
or epoxidation, but rather it catalyzes a rearrangement reaction. The reaction carried out by the 
“non-classical” pathway bears some resemblance to the “classical” pathway because the Fe(III) 
of the heme reacts with an endoperoxide oxygen in a similar fashion to other P450s reacting with 
a dioxygen molecule. The substrate of CYP5A1 is prostaglandin H2 (PGH2), which is derived 
from arachidonic acid. PGH2 is rapidly isomerized to TXA2, a bioactive molecule that degrades 
thromboxane B2 (TXB2), a less active molecule that is much more stable. Another P450 that 
carries out a similar reaction is CYP8A1, which isomerizes PGH2 to prostacyclin. In addition to 
being “non-classical” P450s, both CYP5A1 and CYP8A1 are among the few CYPs that do not 
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have a conserved threonine residue on the I-helix directly above the heme (33-35). Prostanoids 
formed by oxidation or isomerization of PGH2 are produced in a number of different cell types 
(Fig 1.6) (36). 
 
CYP5A1 is most highly expressed in platelets; within platelets its expression level is much 
greater than all other CYPs combined (37). This is not surprising since TXA2 plays a key role in 
platelet aggregation and in the related function of vasoconstriction. The temporal nature of these 
biological processes may explain why such a short-lived molecule would be responsible for their 
mediation. While CYP5A1 and its product, thromboxane or TXA2, are essential, over activity of 
this enzyme can be detrimental to heart health (38). The production of prostacyclin by CYP8A1 
in endothelial cells leads to vasodilation and inhibits platelet aggregation, balancing the effects of 
thromboxane (Fig 1.7). 
 
Although CYP5A1 and CYP2J2 are both involved in eicosanoid biosynthesis, their products can 
have opposite effects. Specifically, the product from CYP5A1 promotes platelet aggregation and 
vasoconstriction, whereas CYP2J2 products inhibit platelet aggregation and promotes 
vasodilation (29). 
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Chapter Figures 
 
 
 
 
 
FIG 1.1: CONSERVED SECONDARY STRUCTURAL ELEMENTS OF P450S. Topology drawing of P450BM-P is shown with helices represented by 
black bars. The length of each of the bars is in approximate proportion to the length of the helix. The strands of -sheets are shown with arrows. 
The strands are grouped by the secondary structural elements which they comprise. The structural elements are grouped into the -helical-rich 
domain and the -sheet-rich domain. The heme is shown by the square at the NH2-terminal end of the L-helix. With permission of Springer. Taken 
from Cytochrome P450: structure, mechanism, and biochemistry, p. 157 (4). 
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FIG 1.2: CYTOCHROME P450 NOMENCLATURE. This example of the name for a particular P450 polymorphism indicates which part of the name 
correspond to family, subfamily, locus, and polymorphism (5). 
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FIG 1.3: P450 CATALYTIC CYCLE. The P450 catalytic cycle includes binding of substrate (RH), transfer of two electrons (e
-
) from a protein redox 
partner, binding of molecular oxygen, and transfer of two protons (H
+
) from solution. Hydroxylation of substrate by Compound I is shown. 
Uncoupling reactions are indicated by three shunt pathways. Image adapted with permission from (10).   
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FIG 1.4: ARACHIDONIC ACID METABOLISM BY SUBFAMILY 2J. Known reactions of arachidonic acid (center) by CYPs in subfamily 2J 
from various species are shown. The reactions of CYP2J2 that form four EETs and two HETEs are highlighted. Image adapted with 
permission from (14). 
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FIG 1.5: PHYSIOLOGICAL EFFECTS OF CYP2J2. Metabolites produced by CYP2J2 in endothelial cells can act in autocrine and paracrine 
fashion to affect various processes (boxed) by modulation of the levels of specific proteins and cellular metabolites. Image reprinted 
from (12) with permission from Elsevier. 
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FIG 1.6: BIOCHEMICAL PATHWAYS FOR PROSTANOID PRODUCTION. Cyclooxygenase (COX) produces PGH2, which serves as a substrate for 
enzymes in various tissues. Prostaglandin E synthase (PGES) produces PGE2, prostaglandin D synthase (PGDS) produces PGD2, prostacyclin 
synthase (PGIS or CYP8A1) produces PGI2, thromboxane synthase (TXS or CYP5A1) produces TXA2, and prostaglandin F synthase (PGFS) 
produces PGF2. CYP5A1 and CYP8A1 are isomerases both lacking the highly conserved I-helix threonine residue. Image adapted with 
permission from (36). 
 
 
 
  
13 
 
 
 
 
 
 
 
 
FIG 1.7: PHYSIOLOGICAL RELEVANCE OF CYP5A1. Thromboxane, produced by CYP5A1 in platelets, and prostacyclin, produced by CYP8A1 in 
endothelial cells, are prostanoids which lead to opposite effects. These are important in the balance of vasoconstriction versus vasodilation and in 
the induction of platelet aggregation. 
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CHAPTER 2: PREPARATION OF CYP AND CPR 
 
Expression and purification of CYP and CPR for biochemical assays 
 
Both CYPs and CPR were obtained in sufficient quantities for biochemical assays described here 
by heterologous expression in the DH5 strain of Escherichia coli. The protocols used were 
those previously optimized by others who were purifying these same proteins. Important factors 
that were optimized which can have an impact upon protein yield from E. coli cultures include 
volume of culture, optical density (O.D.) at time of induction, temperature following induction, 
rotation speed following induction, and time for expression following induction. 
 
Procedure for expression and purification of CYP2J2 and CYP5A1 
 
The CYP2J2 and CYP5A1 constructs were cloned into the pCWori vector (39) and were co-
transformed with the pGro7 vector (Clontech Laboratories Inc.). The pGro7 vector encodes 
GroES and GroEL. In brief, an overnight starter culture grown in LB media was briefly diluted 
100-fold and used to inoculate 500 ml of TB media supplemented with chloroamphenicol (20 
µg/ml) and ampicillin (100 µg/ml). δ-aminolevulinic acid was added at a final concentration of 
0.5 µM after 2.5 h at 37 °C and 220 rpm. The culture was then grown at 26 °C and 160 rpm for 
approximately another 2.0 h until it had reached an O.D. of 1.2 absorbance units. CYP and 
chaperonin expression were induced by the addition of IPTG at a final concentration of 1 mM 
and arabinose at a concentration of 4 mg/ml. Cultures were grown for 44 h before isolating the 
whole cell fractions by centrifugation at 6000 g (39, 40). Cells were resuspended in buffer and 
sonicated (7 cycles x 30 s) using a Heat Systems Ultrasonics sonicator set at an output level of 4 
and a 80% duty cycle. Cell debris was removed with a 10 minute spin at 6000 g and then the 
membrane fraction was pelleted with a 105,000 g, 45 minute, 4 °C spin in a Beckman 
Ultracentrifuge (Beckman Coulter, Brea, CA). The membrane fraction was then resuspended in 
buffer containing 100 mM potassium phosphate (pH 7.4), 20% glycerol, 200 mM sodium 
chloride, 0.1 mM dithiothreitol (DTT), and 0.5% sodium cholate for 4-6 h at 4 °C. An additional 
ultracentrifugation using the same speed and duration was performed to isolate the supernatant 
containing the solubilized target protein. A Ni-NTA column was equilibrated with 100 mM 
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potassium phosphate (pH 7.4), 20% glycerol, and 0.5% detergent. After the protein sample was 
loaded, the column was washed with 5 column volumes of the equilibration buffer containing 20 
mM imidazole. To remove bound GroES and GroEL the column was washed with 5 column 
volumes of the equilibration buffer containing 5 mM ATP, 10 mM magnesium chloride, and 150 
mM potassium chloride. Finally, the protein was eluted with equilibration buffer containing 200 
mM imidazole (CYP2J2) or histidine (CYP5A1). The eluate was then buffer exchanged to 
remove imidazole or histidine and concentrated using Amicon centrifugal filters (Millipore, 
Milford, MA) with MW cut off of 10 kDa and was frozen at -80 °C. 
 
Procedure for expression and purification of CPR 
 
The CPR (Rattus norvegicus) transformed in E. coli was grown in LB media as previously 
described in detail (39). In brief, cells were pelleted by centrifuging at 6000 g for 15 min at 4 °C 
and resuspended in cold lysozyme buffer (75 mM Tris-HCl (pH 8.0), 0.25 M sucrose, 0.25 mM 
EDTA, and 0.02 mg/ml lysozyme) for protease inhibition. Removal of the lysozyme buffer was 
accomplished via centrifugation at 2500 g for 30 min using a JA-10 rotor (Beckman Coulter, Inc) 
at 4 °C. The resultant spheroplasts were resuspended in lysis buffer (50 mM Tris pH 8.0 and 1 
mM PMSF) at 4 °C and further sonicated as described above. E. coli membranes were isolated 
by ultracentrifugation at 105,000 g for 30 min at 4 °C. The membrane pellet was then solubilized 
in column buffer (50 mM Tris pH 7.7, 20% glycerol, 0.1 mM EDTA and 0.1 mM DTT) 
containing 0.2% Triton X-100 at 4 °C. After ultracentrifugation of this solubilized pellet, the 
supernatant fraction containing the protein was loaded onto a 2′,5′-ADP agarose column 
equilibrated with the column buffer. The protein was eluted with elution buffer containing 2 mM 
NADP. Detergent removal was accomplished by purification using a DEAE column and eluting 
in the presence of 500 mM NaCl. The final CPR concentration was measured with a Cary Bio 
300 UV–Vis spectrophotometer (Agilent Technologies) at 456 nm using a molar extinction 
coefficient of 21,400 M
-1
cm
-1
.  
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Site-directed mutagenesis using inverse PCR 
 
Techniques for site-directed mutagenesis of DNA contained within a plasmid are not new. 
Invariably, the available strategies make use of PCR to introduce mutations via modifications in 
PCR primers. Many of these require ligation of multiple PCR products and/or plasmid 
sequences. Here we have developed a technique for mutagenesis that permits amplification of a 
single product, followed by a cohesive-end ligation that does not alter the original sequence.  
 
Class-IIS restriction enzymes have been recognized for a number of years as being useful tools 
for the manipulation of DNA sequences (41). Among restriction endonucleases they are unique 
in that instead of binding and cleaving at a palindromic site, they bind a non-palindromic 
sequence and then cleave in a consistent fashion at an adjacent sequence. Therefore, the 
manipulations with such enzymes can be seamless, implying that the restriction enzyme site used 
to create a site for ligation need not be part of the final product. 
 
An early application of this class of enzymes involved the class-IIS enzyme Eam1104I (42). 
PCR products were created such that this site could be cleaved from each end at precise distances 
from the regions to be ligated. This technique avoided the problem of internal restriction sites by 
incorporating methylated dCTP into the PCR products, thus inhibiting the enzyme at any site not 
containing unmethylated primer DNA. Cutting at unintended sites is a reasonable concern; for 
example the non-palindromic 6-base recognition site of Eam1104I would be expected to 
randomly appear at a frequency of 1 per 2048 base pairs of DNA. 
 
A later application of this technique was employed in random mutagenesis strategy that involved 
amplification of an entire plasmid (43). In this technique the class-IIS enzyme with a 6-base 
recognition site, BsaI, was used to cleave the ends of the PCR products prior to ligation. Since 
the goal of this project was the directed evolution of a 4-amino acid region of a protein, this 
technique allowed the flexibility of multiple mutagenesis rounds in which the pool of starting 
material varied widely in sequence because the restriction site could be placed immediately 
adjacent to the variable region in seamless fashion. It should be noted that this application relied 
on the fact that there were no internal BsaI sites within the vector being mutated. In addition, in 
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order to screen millions of products the ligation step needed to be efficient; the fact that the 
ligation involved a cohesive end rather than a blunt end was critical for maintaining a high level 
of ligation efficiency. This published technique (43) was based on a protocol developed by D. 
Meling (unpublished data). 
 
A technique termed Golden Gate cloning has also taken advantage of this class of restriction 
enzymes (44-47). This is a strategy that calls for the PCR amplification multiple genes with BsaI 
sites at either end of the product. Enzymatic digestion results in products with two different 
cohesive ends amenable to ligation. Multiple products are then ligated simultaneously as the 
resulting cohesive ends are planned such that the gene products will ligate in a pre-specified 
order. 
 
The technique we have devised utilizes a class-IIS enzyme with a 7-base recognition site, BspQI, 
an isoschizomer of SapI. This greater size of the recognition site gives the added advantage that 
the random occurrence of non-desired internal sites would be 1 per 8192 base pairs rather than 1 
per 2048 base pairs; the smaller size of the overhang, 3 bases versus 4 bases, is a slight 
drawback. This technique is a modification of enzymatic inverse PCR (EIPCR) mutagenesis 
utilizing BsaI (48). In addition to amplifying the entire plasmid with back-to-back mutagenic 
primers, our technique also has been attempted in cases where there are up to 3 internal SapI 
sites in the plasmid. The ligation of these plasmid fragments in proper order is similar to the 
assembly of multiple PCR products using the Golden Gate cloning methodology; in such cases it 
is necessary to design primers such that there will not be duplicate DNA overhangs. 
 
This method is an improvement upon our use of the inverse PCR (IPCR) that relies on ligation of 
phosphorylated, blunt-ended products (49). The lower efficiency that results from the need to 
phosphorylate the DNA and the lower efficiency of blunt-ended ligations is overcome with the 
incorporation of a class-IIS enzyme into the protocol. 
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Procedure for blunt-ended inverse PCR 
 
Primer design for inverse PCR requires that there be two back-to-back primers—those that 
recognize opposing strands of the template, whose 5’ ends are in close proximity, and whose 3’ 
ends are separated by the length of the two primers. For blunt-ended inverse PCR, the 5’ end 
nucleotide of each primer recognizes a different location on the template and there is no gap 
between these two nucleotides. To assist in the screening process and avoid ligation products that 
may have a few extra nucleotides inserted at the juncture, most primer pairs were designed in 
such a fashion that a restriction site resulting in a silent mutation was incorporated. This 
restriction site was split between the 5’ ends of each primer so that extra nucleotides at the 
junction would destroy the palindromic recognition sequence. Such a diagnostic restriction site 
was placed within 10-15 nucleotides of the desired mutation, if possible, so that the mutation 
would not be too close to the 3’ end of either primer. Primers were designed to have melting 
temperature of close to 65 °C and were checked for primer dimers with NetPrimer software 
(PREMIER Biosoft). Exact matches of 3 or more bases at the 3’ end, either as a hairpin, with the 
same primer, or with the opposite primer, were avoided if possible. When possible the general 
rules followed for the 3’ end of the primer were: (1) a final nucleotide of G or C to increase 
binding, and (2) at least one A or T in the final 5 nucleotides to avoid non-specific binding. 
 
To make possible the ligation of the blunt-ended PCR products, one of the two primers used for 
inverse PCR was phosphorylated prior to PCR. A reaction containing 20 pmol/l of the 
designated primer was prepared and this was used directly as a 20x stock for subsequent PCR 
reactions. Incubations were performed at 37 °C for one hour with 0.2 U/l of T4 Polynucleotide 
Kinase (New England Biolabs). The enzyme was deactivated by incubating at 65 °C for 20 
minutes. Reactions also included 1x buffer supplied by the manufacturer, 1 mM ATP, and 0.5 
mM DTT. 
 
The inverse PCR reactions were performed using a final concentration of 0.2 ng/l of template 
DNA, 0.02 U/l of Phusion HF DNA Polymerase (New England Biolabs), and 0.2 mM of each 
dNTP. A 1x reaction buffer consisting of either HF or GC buffer supplied with the enzyme was 
used. In addition, optimization of each individual reaction was performed by raising the MgCl2 
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concentration from 2.0 mM to 2.5 or 3.0 mM with a stock of MgCl2 that accompanied the 
enzyme. Most reactions gave higher yields upon the addition of a final concentration of 10% 
DMSO. Time and temperature parameters for the thermal cycler were: 3 min at 96 °C; 20 cycles 
of 30 s at 96 °C, 30 s at 55 °C, and 8 min at 72 °C; and, 3 min at 72 °C. 
 
Following PCR, reactions were run on a 0.8% agarose gel to separate the full-length product 
from non-specific products of lesser size. The band of the expected size was then excised along 
with approximately 100 to 200 mg of agarose. This was purified using a QIAgen Gel Extraction 
Kit (QIAGEN Sciences) and eluted in a volume of approximately 40-50 l of water. T4 DNA 
Ligase (New England Biolabs) was added at 10 U/l along with enough ligase buffer to make 
the buffer concentration 1x, and the mixture was then incubated for 16 hours at 16 °C. The entire 
reaction volume was then drop dialyzed by pipetting onto a 0.025 m nitrocellulose membrane 
(Millipore, VSWP04700) floating on approximately 10 ml of water for 20 minutes. The reaction 
was then transformed into CaCl2 competent DH5 E. coli cells. This procedure required heat 
shock at 42 °C for 60 seconds, recovery for one hour in SOC media, and overnight growth on 
LA plates supplemented with ampicillin (100g/ml). Several transformants were purified using a 
QIAprep Spin Miniprep Kit and were screened for incorporation of a diagnostic restriction site 
incorporated via the primer sequences. DNA samples that passed the initial screening were 
sequenced at the UIUC Core Sequencing Facility (Urbana, Illinois) using primers that match the 
pCWori vector near either end of the cloning site. 
 
Procedure for class-IIS inverse PCR 
 
Primer design for inverse PCR with a class-IIS restriction enzyme is similar to that for blunt-
ended inverse PCR (Fig 2.1). Primers were designed such the 3-nucleotide overhang following 
restriction with BspQI would be at the same location in the template following digestion. The 
desired mutation was incorporated into the overhang region of both primers and/or immediately 
3’ of the overhang region in one of the primers. Digestion of the product ends greatly decreases 
the likelihood of additional undesired nucleotides, so a diagnostic restriction site as part of a 
silent mutation was not incorporated into primers for this strategy. An additional 14 nucleotides 
were needed in each primer 5’ of the overhang region. These nucleotides in order from the 5’ end 
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were: (1) 6 random nucleotides for restriction enzyme binding; complementarity to template was 
preserved as much as possible while avoiding primer dimer issues, (2) a non-palindromic 
recognition sequence of 5’-GCTCTTC-3’, and (3) a requisite single nucleotide before the 
restriction site; complementarity to template was preserved if there were no primer dimer issues. 
A melting temperature of close to 65 °C was targeted from the overhang region to the 3’ end of 
the primer, where there was an exact match. The same criteria regarding primer dimers and the 
3’ end sequence were used as for blunt-ended inverse PCR. (For a list of primers, see Table 5.1) 
 
For class-IIS inverse PCR adding a 5’ phosphate group to the primers and/or the product was 
unnecessary due to the fact that a 5’ phosphate group remains following digestion. The PCR 
program used was essentially the same as described for blunt-ended inverse PCR, and the 
optimization parameters were the same. Gel extraction was the same as described for blunt-
ended inverse PCR. 
 
In the case of class-IIS PCR a digestion step not present in the blunt-ended procedure is required. 
Therefore, reaction buffer provided for BspQI (New England Biolabs) was added so that the 
eluted DNA was in 1x reaction buffer. BspQI was added at 0.1 U/l and incubated for 3 h at 50 
°C for digestion and 10 min at 80 °C for enzyme denaturation. The entire reaction volume was 
then drop dialyzed by pipetting onto a 0.025 m nitrocellulose membrane (Millipore, 
VSWP04700) floating on approximately 10 ml of water for 20 min. Following drop dialysis 
approximately 20 l of the reaction was recovered and ligase buffer was added such that the 
recovered DNA was in 1x buffer. Ligation, drop dialysis, transformation, and plasmid 
purification were then carried out as with the blunt-ended procedure. 
 
Screening of the isolated DNA with the class-IIS procedure did not involve incorporation of a 
novel restriction site via the primers. Therefore, initial screening involved digestion with an 
enzyme that occurred more than once in the plasmid to check for proper reassembly of the 
multiple fragments created during BspQI digestion. Those DNA samples that passed the initial 
screen were sequenced as described previously. 
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Construction of a CYP2J2 homology model 
 
Due to the absence of a crystal structure for CYP2J2, a three-dimensional homology model was 
created using a previously established approach (50). This procedure was carried out using 
Molecular Operating Environment software (MOE; version 2011; Chemical Computing Group, 
Inc., Montreal, Canada).  
 
First a primary sequence alignment with other family 2 CYPs that had available crystal structures 
was obtained using the BLOSUM62 scoring matrix (51) in the ALIGN function in MOE. Those 
existing structures were for CYP2A6, CYP2B4, CYP2C5, CYP2C8, CYP2C9, CYP2D6, 
CYP2E1, and CYP2R1 (52-59). Among these, the highest percentage sequence homology was 
with CYP2B4, so this was used as an overall template to align CYP2J2. Next, a hybrid model 
was created by substituting in coordinates from the list of family 2 structures in each of three 
hypervariable regions that are important in substrate binding. Based upon primary sequence 
homology, CYP2C8 was used for the B region, CYP2R1 was used for the F-G region, and 
CYP2C9 was used for the 4 region (Fig 2.2, Fig 2.3). 
 
Homology models for CYP2J2 were made using the HOMOLOGY function of MOE. Ten of 
these candidate models were evaluated based upon packing score, and the best model was 
chosen. To add the heme, a 3-D alignment was performed with another CYP already containing 
a heme. After removal of the amino acids of the other CYP, the Fe of this heme was bonded to 
C448 of CYP2J2. Finally the structure was further energy minimized using the CHARMM22 
force field (60), which is necessary when there is a heme in the model. Additional verification 
was performed with Ramachandran plots to verify that there were no torsional outliers (61).  
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Chapter Figures 
 
 
 
 
 
 
FIG 2.1: INVERSE PCR WITH TYPE IIS RESTRICTION ENZYMES. This schematic outlines the mutagenesis procedure used for these projects. The 
first step is inverse PCR of the entire plasmid. After gel purification the next step is digestion with BspQI (at sites labeled “B”). Finally small 
fragments are removed with drop dialysis, the remaining large fragments are ligated, and the reconstituted plasmid is transformed into bacteria. 
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FIG 2.2: CYP2J2, CYP2C8, CYP2R1, AND CYP2B4 ALIGNMENT. Clustal W alignment made in Biology Workbench (workbench.sdsc.edu) for 
CYPs used in the homology model. Substrate recognition site (SRS) regions are highlighted in yellow. Helical regions A-L are denoted with 
capital letters. The following regions whose Protein Data Bank (PDB) coordinates were used for the model are highlighted: (1) the B region for 
CYP2C8 in blue, (2) the F-G region for CYP2R1 in red, and (3) the 4 region for CYP2C9 in purple. CYP2B4 coordinates were used for the 
overall backbone of the model. 
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FIG 2.2: CYP2J2, CYP2C8, CYP2R1, AND CYP2B4 ALIGNMENT (CONTINUED). 
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FIG 2.3: HYBRID MOE MODEL OF CYP2J2. The overall backbone is based on coordinates of CYP2B4 (42% homology). The B region (in blue) 
is based on coordinates of CYP2C8 (38% homology). The F-G region (in red) is based on coordinates of CYP2R1 (40% homology). The 4 
region (in purple) is based on coordinates of CYP2C9 (26% homology). 
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CHAPTER 3: ELECTRON TRANSFER KINETICS 
 FROM CPR TO CYP2J2
1
 
 
Abstract 
 
CYP2J2 epoxygenase is a membrane-bound cytochrome P450 primarily expressed in the heart and plays 
a significant role in cardiovascular diseases. The interactions of CYP2J2 with its redox partner, 
cytochrome P450 reductase (CPR), and with its substrates are quite complex and can have a significant 
effect on the kinetics of substrate metabolism. Here we show that the N-terminus of CYP2J2 plays an 
important role in the formation of CYP–CPR complex for subsequent electron transfer. We demonstrate 
that when CYP2J2–CPR are pre-incubated before the onset of reduction, the kinetics of reduction is 
triphasic and is of a similar order of magnitude to previously reported rates in other cytochrome P450 
systems. However, when CYP2J2 and CPR form a complex during the time course of the experiment the 
kinetics of the fastest phase for N-terminus containing full-length CYP2J2 is 200 times faster than the 
kinetics of reduction of N-terminally truncated CYP2J2. Hence, we show that the N-terminus of CYP2J2 
is very important to form a productive CYP–CPR complex to facilitate electron transfer. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
____________________________________ 
1
This chapter appeared in its entirety in the Journal of Inorganic Biochemistry. Meling, D.D., McDougle, D.R., and 
Das, A., 2014. “CYP2J2 Epoxygenase Membrane Anchor Plays an Important Role in Facilitating Electron Transfer 
from CPR.” 142:47-53 (62). This article is reprinted with permission of the publisher. This chapter has minor 
changes, has some omissions, and contains additional material not found in the original publication.  
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Introduction 
 
CYP2J2 epoxygenase is a membrane-bound cytochrome P450 that is primarily expressed in the 
heart. It plays a signiﬁcant role in cardiovascular diseases, inﬂammation, and cancer (63-65). Its 
effects are mediated by catalyzing the epoxidation and/or hydroxylation of both -3 and -6 
polyunsaturated fatty acids (PUFAs) (66-70). Speciﬁcally, CYP2J2 converts arachidonic 
acid (AA) into four regioisomeric cis-epoxyeicosatrienoic acids (EETs), which have been 
shown to be cardioprotective (19, 65). The EETs induce angiogenesis, have anti-inﬂammatory 
effects, and protect the heart and brain from ischemic damage (19). CYP2J2 is also 
important for the metabolism of several antihistamine drugs such as ebastine and terfenadine, 
which have been implicated in cardiotoxicity via Q–T prolongation (19, 68, 70-72). 
 
CYP2J2 catalyzes epoxidation/hydroxylation of PUFAs by inserting one atom of molecular 
oxygen into its substrates while simultaneously directing the other atom of oxygen into water 
(10, 73). This reaction requires electrons that are derived from NADPH and are delivered via 
the obligate redox partner, cytochrome P450 reductase (CPR). The ﬁrst electron transfer from 
CPR facilitates the formation of the reduced CYP. This ﬁrst electron transfer step is studied by 
trapping the reduced Fe(II) state of CYP2J2 in the presence of carbon monoxide, which leads to 
the formation of an Fe(II)–CO complex. 
 
Despite extensive studies on this ﬁrst step of electron transfer in reconstituted systems (74-
81), there are several questions that remain unanswered with regard to the role of the 
following factors on the ﬁrst electron transfer rates. Firstly, what is the putative role of the 
N-terminal membrane-anchoring domain of CYP in the formation of CYP–CPR complex to 
facilitate electron transfer? Secondly, do substrates that cause minimal spin-state shift alter 
the electron transfer rate? Thirdly, is the electron transfer rate controlled by the oligomeric 
state of the CYP? 
 
Previous studies have shown that the rate of ﬁrst electron transfer of microsomal cytochrome 
P450s leads to a biphasic nature of the reduction kinetics (79, 82). Additionally, it has been 
shown that the reduction kinetics of the P450 varied with the identity of the P450. For instance, 
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under certain conditions, CYP1A1 showed single exponential kinetics while CYP3A4 and 
CYP2E1 exhibited biphasic kinetics (83). There are three different hypotheses that have been 
proposed to explain the observed multiphasic kinetics of ﬁrst electron transfer. The ﬁrst hypothesis 
is that multiphasic reduction kinetics is due to a dynamic equilibrium among different 
conformations of the CYP–CPR complex (79). In this model there is an optimal conformation 
for electron transfer from CPR to the ferric species of CYP, which results in the fastest phase. In 
addition, there are slower phases observed because of other conformations. 
 
Herein, we show that the N-terminus of the CYP is important in the formation of complexes with 
CPR. The presence of the N-terminus greatly inﬂuences the rates and relative amplitudes of 
the different kinetic phases, which presumably represent different conformations of the 
complex. The second hypothesis proposes that the multiple phases correspond to the reduction 
of the two different sub-populations of high spin (faster rate) and low spin (slower rate) in the 
protein population. The rate of spin state conversion is rapid and the formation of an Fe–CO 
complex is also a rapid process in itself, therefore it is highly unlikely that the sub-population of 
spin states is controlling the multiphasic kinetics. Additionally, for one of the bacterial systems 
it has been shown that spin state and ﬁrst electron transfer are correlated, but for the 
microsomal systems this correlation is weak (84, 85). There are several human P450s, 
including CYP2J2, where a native substrate, arachidonic acid in this case, does not elicit a 
substantial change in the spin state upon binding. To evaluate how spin state change can 
affect electron transfer rate, the experiments were performed with different substrates. This 
study gives us an opportunity to compare electron transfer rates using substrates such as 
ebastine that induce a signiﬁcant spin state change in CYP2J2 versus a silent endogenous 
substrate, arachidonic acid, that shows negligible spin-state change on binding CYP2J2. The 
third hypothesis is that the multiphasic reduction kinetics comes from the different 
aggregation states of the membrane-bound P450s. To test this hypothesis, we control the 
oligomeric state of CYP2J2 in a lipid bilayer environment of Nanodisc before the electron 
transfer studies. Incorporating a membrane protein into Nanodiscs mimics the endogenous 
membrane environment of the protein (Fig 3.3) (86, 87). In general the oligomeric state of the 
protein can be precisely controlled (88 ) . Nanodiscs are an important tool for the 
solubilization and biochemical investigation of many diverse membrane protein systems 
29 
( 8 6 ,  8 9 ,  9 0 ) . 
 
In general, the ﬁrst electron transfer of the P450 cycle requires the association of a CYP 
and its redox partner CPR and the role of the N-terminus of the CYP in that association has 
not been clearly delineated. In the cellular environment, the CPR:CYP ratio is low and the ﬁrst 
step of association of CYP and CPR can be the rate-limiting step for the CYP reduction in 
the P450 cycle (7, 91, 92). Previous studies have used either full-length proteins isolated 
from microsomes or truncated recombinantly expressed CYP for their respective electron 
transfer studies (79, 82) . Therefore, a study that uses both full-length and N-terminally 
truncated CYP for electron transfer studies to elucidate the role of the membrane anchoring 
CYP domain in protein–protein interaction would be useful. Previously, we have successfully 
expressed both the full-length CYP2J2 (termed here as CYP2J2ﬂ, previously termed as “SMG” 
(silent mutation g-chaperonin) (39, 40), and completely N-terminally truncated CYP2J2 
(termed here as CYP2J2tr, previously termed as “D34”). Herein, we use these two constructs 
of CYP2J2 to provide evidence that the membrane anchoring N-terminus domain of a CYP is 
key in facilitating the formation of the complex with CPR for subsequent electron transfer from 
CPR to CYP. 
 
In this work, we use stopped ﬂow spectroscopy to study the role of the substrate, oligomeric 
state, and N-terminus membrane anchoring domain of CYP2J2 on the ﬁrst electron transfer 
from CPR to CYP. We unveil a novel role of the N-terminus membrane anchoring domain of 
CYP2J2 in facilitating association with CPR and enhancing electron transfer. 
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Materials and Methods 
 
CYP2J2-Nanodisc preparation 
 
Nanodiscs were prepared as previously reported (39 ) . The net neutral lipid POPC was 
lyophilized and reconstituted with 20 mM sodium cholate. The resultant lipids were then 
mixed with the membrane scaffold protein MSP1E3D1(−) (130:1 ratio), devoid of the 
typical histidine afﬁnity tag. An MSP:CYP ratio of 15:1 was used for incorporation. Amberlite 
beads were used for detergent removal to initiate the Nanodisc assembly process. CYP-
containing Nanodiscs were puriﬁed on a Ni-NTA column followed by size exclusion 
chromatography for isolation of a homogenous and monodisperse population. 
 
Binding titration of CYP2J2tr-Nanodiscs with ebastine and arachidonic acid 
 
The afﬁnity of binding of ebastine and arachidonic acid to CYP2J2 was calculated by 
monitoring differences in absorbance using a Cary Bio 300 UV–Vis spectrophotometer 
(Agilent Technologies). The titration mixture contained 2 μM of CYP2J2-ND, 100 mM 
phosphate buffer (pH 7.4), and ebastine or arachidonic acid. Ebastine was added 
incrementally from a 10 mM stock in ethanol. The arachidonic acid was added from variable 
stocks of 5 mM to 50 mM in DMSO. For both titrations the level of organic solvents in the ﬁnal 
titration mixture was kept < 1% (v/v). The absorption spectra were measured between 800 
and 200 nm after each addition of substrate. Spectra were plotted and analyzed using a standard 
MATLAB subroutine and ﬁtting was done using OriginLab.  
 
Δ(A393 −A417) = AmaxS/[Ks(app) + S]   (Equation 3.1) 
 
As shown in Equation 3.1, ΔA is the absorbance difference at 393 and 417 nm for ebastine 
(or 434 and 411 nm for arachidonic acid), Amax is the amplitude which corresponds to 
maximum absorbance difference extrapolated to an inﬁnite ligand concentration, Ks(app) is 
the spectral dissociation constant, and S is the substrate concentration. 
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Binding titration of CYP2J2-nanodiscs with CPR 
 
The titration was performed and analyzed using a tight binding Morrison quadratic as given 
in Equation 3.2. The difference in absorbance is monitored at 390 and 417 nm. The 
concentration of the CYP2J2 used was 0.5 μM. A 30 μM stock of CPR was added so that the 
ﬁnal concentration ranged from 0.05 μM to 5.0 μM. 
 
ΔA(390-417)=(Amax)
([𝐶𝑌𝑃]+[𝐶𝑃𝑅]+𝐾𝑠(𝑎𝑝𝑝))−√([𝐶𝑌𝑃]+[𝐶𝑃𝑅]+𝐾𝑠(𝑎𝑝𝑝))
2−4[𝐶𝑌𝑃][𝐶𝑃𝑅]
2[𝐶𝑌𝑃]
   (Equation 3.2) 
 
As shown in Equation 3.2, ΔA is the absorbance difference at 390 and 417 nm, Amax is the 
maximum absorption, [CYP] is the concentration of CYP2J2, [CPR] is the concentration of 
CPR, and Ks(app) is the apparent spectral binding constant. The calculated binding constants are 
averages of multiple independent experiments. 
 
Electron transfer kinetics by stopped flow experiments 
 
The reduction measurements were made using an Applied Photophysics SX-17 MV 
Spectrophotometer (Leatherhead UK). The ﬂow cells and syringes in the instrument system 
were made anaerobic by multiple washes with decreasing concentrations of dithionite (from 
approximately 2.5 mM to 2.5 μM), which was used to scavenge oxygen in the system and 
make it anaerobic. The dithionite stocks were prepared fresh in an anaerobic glove box with 
anaerobic 0.1 M phosphate buffer; the original stock of dithionite was approximately 15 mM. 
Dithionite washes were followed by multiple rounds of washes with anaerobic phosphate 
buffer containing the same oxygen scavenging system present in the samples. This oxygen 
scavenging system consisted of 1 U/ml freshly prepared glucose oxidase (bioWORLD catalog 
number 21560012-1) and 35 mM glucose. The glucose was from a 1.4M anaerobic stock 
which was added to each sample in an anaerobic glove box. 
 
Two reaction cells in the stopped ﬂow system were used. In pre-incubation studies, the ﬁrst 
reaction cell contained 2 μM CYP2J2 either in 0.1% cholate or in Nanodiscs. CPR was also 
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present at a concentration of 6 μM in the same reaction cell as CYP2J2. The second reaction 
cell contained excess NADPH at a concentration of 1 mM. For association-dependent studies, 
the ﬁrst reaction cell contained 2 μM CYP2J2 and 1 mM NADPH while the second reaction 
cell contained 6 μM of CPR. Samples were made anaerobic by purging with nitrogen gas for 20 
minutes to remove oxygen and the samples not containing CYP were then purged with carbon 
monoxide for 5 minutes. The air-tight Hamilton syringes (Gastight #1001) containing these 
samples were assembled in the COY glove box. To keep an anaerobic environment, a rubber 
stopper (Suba-Seal #13) was used to replace the needle that drew the sample and Parafilm was 
wrapped around the stopper. Samples were transported on ice and were then equilibrated to 25 °C 
before the onset of the experiment. In all cases, the reduction of ferric CYP2J2 to form a 
ferrous–CO complex was monitored at 449 nm upon mixing the two separate reaction cells. 
 
Data analysis 
 
The stopped ﬂow data were collected in logarithmic mode in which absorption data for each run 
were collected as a logarithmic function of time upon mixing to ensure that all kinetic phases 
were adequately sampled. Those data indicate the average of two to eight individual reactions. 
Absorbance spectra were collected using Applied Photophysics software. The data points for 
absorbance at 449 nm versus background at 801 nm were ﬁtted by using a three-summed 
exponential equation from OriginLab software. R2 values for ﬁts exceeded 0.99 in most cases. 
Experiments which showed monophasic kinetics yielded a single rate constant from this same 
equation. A three-summed exponential was used to describe multiphasic kinetics using the 
following equation. 
 
yo - y = (A1)e
-k
1
t
 + (A2)e
-k
2
t
 + (A3)e
-k
3
t   
(Equation 3.3) 
 
 
In Equation 3.3 yo is maximal amplitude and y is amplitude at any given time. The three 
amplitudes are represented by A1, A2, and A3. The rate constants are represented by k1, k2, and 
k3 and time is denoted by t. 
 
The errors reported are standard errors of the mean.  
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Results 
 
The full-length CYP2J2ﬂ and truncated CYP2J2tr were expressed and puriﬁed using published 
methods (39,  40 ) . As previously described, CYP2J2 was incorporated into the membrane 
bilayers of Nanodiscs (Fig 3.3) (39). An endogenous substrate of CYP2J2, arachidonic acid is 
metabolized to EETs with a very low rate of formation of 65 pmol product/nmol CYP2J2/min at 
30°C (11). The drug ebastine binds to CYP2J2 and produces a signiﬁcant spin state change of 
nearly 90% and a relatively higher rate of production of the primary metabolite 
hydroxyebastine (39). The binding of ebastine (Fig 3.1A) and arachidonic acid (Fig 3.1B) to 
CYP2J2-Nanodisc was measured. While the binding of ebastine leads to the characteristic type I 
spectral change, the binding of arachidonic acid produced minimal spin-state change of less than 
25% accompanied by subtle red shift as seen in Fig 3.1B. By plotting the change in absorbance 
values as a function of ligand concentration, we obtained an apparent Ks of binding for both 
arachidonic acid and ebastine. The apparent dissociation constants for arachidonic acid and 
ebastine were calculated to be 15.1 ± 0.6 μM and 8.2 ± 1.3 μM, respectively (Fig 3.1A &B). 
 
Additionally, we measured the direct interaction of CYP2J2 and CPR by titrating CPR to 
CYP2J2ﬂ and CYP2J2tr. The apparent Ks of CPR binding to CYP2J2ﬂ and CYP2J2tr are 0.58 ± 
0.14 μM and 0.12 ± 0.06 μM, respectively (Fig 3.5). 
 
Measurement of reduction kinetics in CYP2J2-CPR system 
 
We measured the reduction kinetics of the CYP–CPR system (3:1 ratio of CPR:CYP) by 
monitoring the formation of the Fe(II)–CO peak at 449 nm. The increase in absorbance at 449 
nm versus the time was plotted using a MATLAB subroutine (Fig 3.2A). Due to the rapid 
reduction of CPR and the corresponding decrease in absorbance at 449 nm, the ﬁrst 0.2 s of 
data was omitted from these analyses. This reduction kinetics data was ﬁtted to a three-summed 
exponential equation (Equation 3.3) and the rate constants and the spectral amplitudes are 
reported in Tables 3 . 1–3.3. For each experiment examples are shown that include data 
points, a plot of the three-summed exponential equation, and a plot of statistical residuals (see  
Figs. 3.7-3.9). 
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We broadly classiﬁed our electron transfer studies into two main categories: (1) pre-
incubation studies where CYP2J2 and CPR are pre-incubated, thus allowing association before 
being reduced by NADPH in the presence of carbon monoxide, and (2) association-
dependent studies where CYP2J2 and CPR are in separate syringes and therefore associate 
during the time course of the experiment. Most of the previous studies on the measurement of 
electron transfer rates use the pre-incubation method (74, 75, 77). These two different types 
of studies provide novel insights into the role of the association of CYP and CPR during 
electron transfer and how this association is dependent on the CYP N-terminus. Samples were 
prepared in the presence of 0.1% cholate, with the exception of those samples in Nanodiscs. 
 
Pre-incubation studies—kinetics of reduction of CYP2J2 by CPR 
 
Table 3.1 represents the data obtained when CYP2J2 and CPR are pre-incubated and NADPH 
is added to the reaction in the presence of carbon monoxide. The absorbance at 449 nm 
versus time is ﬁtted to a rate equation and the rate constants and amplitudes are reported in 
Table 3.1. These reactions generally ﬁt best to a monophasic exponential equation within the 
ﬁrst 5 s. However, in the fast phase (k1), the reduction of CYP2J2 is approximately only 
halfway completed. Previous studies (74, 75, 77) have focused on the initial kinetics of 
electron transfer (k1). By allowing the reduction to proceed to completion using larger time scale 
measurements we obtained two more rates, k2 and k3, that are reported in Table 3.1. 
 
Pre-incubation studies—effect of substrate binding on the kinetics of reduction 
 
For the CYP2J2tr–CPR system in the presence of arachidonic acid and ebastine the rates are 
0.47 and 1.8 s
−1
 compared to 0.55 s
−1
 for substrate-free (Table 3.1 and Fig 3.7). The electron 
transfer rate is comparable to other systems studied before for substrate-free CYPs (74). 
Interestingly, for the full-length CYP2J2ﬂ–CPR system in the presence of arachidonic acid and 
ebastine the rates are 1.1 and 1.3 s
−1
 compared to 0.69 s
−1
 for substrate-free (Table 3.1 and 
Fig 3.7). Previously, it was shown in CYP3A4 that the substrate-free electron transfer rate is 
0.03 s
−1
 (74). It is 0.10 s
−1
 when it binds erythromycin, which produces minimal spin state 
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change, and it is 12 s
−1
 when binding testosterone, which approximately produces 90% spin 
state change. In our studies, the fast phase rates show a statistically signiﬁcant increase of 2–
3 times with ebastine bound, whereas the fast phase rate with arachidonic acid bound does 
not show a signiﬁcant change. Note that the spin state changes produced by ebastine and 
arachidonic acid are 90% and 25%, respectively. Typically, substrate binding increases the rate 
constants of the fastest phase of electron transfer. Note that arachidonic acid binds and produces 
atypical changes in the Soret band while ebastine binding leads to blue shift of the Soret band 
(Fig 3.1). 
 
Pre-incubation studies—CYP2J2-CPR complexes in Nanodiscs 
 
To evaluate if the different phases in the reduction kinetics are due to the presence of different 
aggregation states of CYP2J2, we incorporated CYP2J2 and CPR in the lipid bilayers of 
Nanodiscs and studied the reduction kinetics. The proteins in the Nanodiscs are devoid of any 
aggregation state and are monomeric in nature (86, 88,  89) . The rates and amplitudes 
for no substrate, arachidonic acid, and ebastine are reported in Table 3.2 and Fig 3.8. Notably, 
these kinetic rates are all of the same order of magnitude as those in the reconstituted 
CYP2J2–CPR system (Table 3.1 and Fig 3.7). Surprisingly, the addition of ebastine does not 
change the electron transfer rates as compared to the substrate-free system. Additionally, 
there are still three phases with similar kinetics of reduction to the reconstituted CYP2J2–
CPR system. These results show that the oligomeric state of CYP2J2 is not the factor that 
leads to multiphasic electron kinetics. 
 
Association-dependent studies—reduction of CYP2J2 truncated by CPR 
 
In the cellular environment the ratio of CPR to CYP is anywhere between 1:10 and 1:100 (91). 
This ratio implies that in vivo CPR needs to associate with CYP and form transient 
complexes to ensure electron transfer. In order to mimic this condition, we measure the 
electron transfer rates in the association-dependent study paradigm. In these studies, CYP2J2 
and CPR need to associate before reduction of CYP during the experimental time scale. We 
performed these experiments to explore the effect of the N-terminus of CYP on electron 
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transfer (Fig 3.4). Our experiments with truncated CYP2J2tr showed a monophasic, very slow 
rate of reduction (Fig 3.4A, Table 3.3 and Fig 3.9). Notably, the rates in Table 3.3 were 
approximately two orders of magnitude less than the fast phase of pre-incubated samples in 
Table 3.1. Also, for CYP2J2tr the relative effect of substrate on k1 in pre-incubated samples 
correlated with the effect of substrate on the association-dependent rates (93, 94). When the 
ratio of CPR:CYP was changed from 3:1 to 1:1, there was a 35% decrease in k1 compared to 
3:1 CPR:CYP. 
 
Association-dependent studies—reduction of CYP2J2 full-length by CPR 
 
The reduction of full-length CYP2J2ﬂ when CPR was added separately gave rates of electron 
transfer that are 200 times more than when CPR was added separately to truncated CYP2J2tr. 
Additionally, the reduction was multiphasic in nature. Moreover, the rate constant k1 of the 
fastest phase is similar to the k1 of the pre-incubated samples (Tables 3.1 and 3.3). It should be 
noted that the second phase has a signiﬁcant decrease in rate compared to the pre-incubation 
scenario. In addition, even though the rate constants are mostly similar for CYP2J2ﬂ in the 
association-dependent experiment, the distribution of CYP in each category is shifted 
drastically, with lower amplitudes for the fastest most highly efﬁcient phase and greater 
amplitudes for the second fastest phase. This observation could not be made previously as 
most studies have used a pre-incubation based method where CYP and CPR were already 
associated in the reaction mixture before the onset of electron transfer. 
 
Association-dependent studies—binding rate of CYP2J2 truncated with oxidized CPR 
 
The rate of association of CYP2J2tr and CPR was monitored by stopped flow kinetics by 
monitoring the difference spectrum between 390 nm and 417 nm. A rate of 1.65 s
-1
 was detected 
for the association of these two proteins in the absence of substrate (Fig 3.6). This is similar to 
the fastest rate seen in this study for electron transfer between CYP2J2 and CPR.  
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Discussion 
 
Despite tremendous progress in research on cytochrome P450s, the interaction of cytochrome 
P450s (CYPs) with CPR, is still not well understood (83, 95). CYPs obtain the electrons required 
for metabolization from NADPH via CPR. Three primary domains comprise CPR: an N-terminal 
membrane anchor, a ﬂavodoxin-like FMN-binding domain, and an FAD- and NADPH-
binding domain. The FMN domain is connected to the FAD domain through a highly ﬂexible 
“hinge”, and recent data show that this domain movement is an essential part of the catalytic 
cycle of CPR (96). 
 
Experimental design 
 
There are numerous studies outlining CYP–CPR interactions by measuring the kinetics of the 
fastest rate of electron transfer under different conditions. However, most of these studies have 
focused on using either full-length CYP isolated from microsomes or recombinantly expressed 
truncated CYP for their respective electron transfer studies (79, 82). As a result, previous 
studies have not been able to directly assess the effects of the CYP hydrophobic N-terminus in a 
single system where the CYP has been isolated from the same source. 
 
We broadly classiﬁed our electron transfer studies into pre-incubation studies where CYP2J2 and 
CPR are pre-incubated before being reduced by NADPH, and association-dependent studies 
where CYP2J2 and CPR are in separate syringes and therefore need to associate before the 
onset of electron transfer. Similar to previous studies (93, 94), this work provides a 
direct comparison of the pre-incubation system with the association-dependent electron 
transfer system to delineate the dependence of ﬁrst electron transfer on productive complex 
formation between CYP and CPR. Additionally, we also studied if substrate binding increases 
the rate constants of the fastest phase of electron transfer. We showed that in the fast phase 
rates increase by as much as 2–3 times upon binding ebastine. 
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Pre-incubation studies 
 
In all experiments where CYP and CPR were pre-incubated, the rate of the ﬁrst electron 
transfer exhibited multiphasic kinetics. We hypothesize that these different phases likely 
represent apparent reduction kinetics of different conformational states that have reached 
equilibrium with each other (79). During the pre-incubated stopped ﬂow experiment three 
processes occur: (1) reduction of CPR by NADPH, (2) electron transfer from CPR to 
CYP2J2, and (3) combination of reduced CYP2J2 with carbon monoxide. Since the reduction 
of CPR by NADPH and the ﬁnal step of binding of the reduced CYP2J2 by CO are known to 
be very rapid (97, 98), the rate-determining step must be the reduction of CYP2J2 by CPR. 
Among the multiple phases that arise prior to reduction, the fastest phase presumably occurs 
in a complex in the most optimal conformation for electron transfer. It is possible that the 
slower phases represent either a rate of conversion from a less optimal conformation to the 
conformation of the fastest phase or simply an inherently slower rate of electron transfer in a 
suboptimal complex of the proteins. 
 
Interestingly, our CYP2J2–CPR-Nanodisc study also shows that it is not the aggregation of the 
CYP that leads to multiphasic kinetics since the CYP in these Nanodiscs has previously been 
shown to be monomeric ( 3 9 ) . Previous studies proposed models where multiple higher 
molecular complexes of CYP–CPR exist (99). These proposed models are in agreement with 
this study where multiple phases arise—most likely due to different conformations of the 
CYP2J2–CPR complex or possibly from interactions of proteins in separate Nanodiscs. 
 
In conclusion, regarding the pre-incubation studies, we notice only minor differences in the 
CYP2J2tr and CYP2J2ﬂ with respect to either the rate of electron transfer or the number of 
phases during electron transfer from CPR. Additionally, the multiphasic reduction kinetics 
does not emanate from differences in the aggregation states of CYP2J2 as demonstrated by the 
pre-incubation studies done in Nanodiscs. 
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Association-dependent studies 
 
We further examine the association-dependent study paradigm to explore the effect of the N-
terminus membrane-anchoring domain of CYP2J2 on electron transfer. In these studies, among 
the four processes, (1) association of CYP2J2 with CPR, (2) reduction of CPR by NADPH, (3) 
electron transfer from CPR to CYP2J2, and (4) combination of reduced CYP2J2 with carbon 
monoxide, the association of CYP2J2 and CPR has the potential to be the rate-limiting step. In 
the cellular environment, the ratio of CPR to CYP is anywhere between 1:10 and 1:100 (91). 
This ratio implies that in vivo CPR needs to continually associate with CYPs and form 
transient complexes to ensure electron transfer. In our studies, we observe that the association-
dependent rate for the fastest phase of the CYP2J2ﬂ reduction is 200 times faster than for 
CYP2J2tr. Therefore, the N-terminus of CYP plays a key role in the association between 
CYP2J2 and CPR to form a productive complex that is amenable to fast reduction. Additionally, 
the rates of electron transfer in association-dependent rates for CYP2J2ﬂ were similar to pre-
incubated samples and they were also multiphasic. A previous study of pre-incubated 
CYP1A1 and CPR shows that perturbing the interaction between CYP and CPR can cause a 
drastic decrease in the rate for the fastest phase of electron transfer (100). Another study of 
CYP2E1 shows that truncation of the N-terminus has little effect on electron transfer rates if 
CYP and CPR are pre-incubated; however, association-dependent rates were not 
investigated (101). These studies indicate that the rates of the fastest phase were quite similar to 
the fastest rates reported here for CYP2J2. 
 
Summary 
 
In order to explain the differences in the association-dependent rates of CYP2J2ﬂ and 
CYP2J2tr, we propose two possible hypotheses: Our ﬁrst hypothesis is that in the association-
dependent electron transfer rate measurement, the rate-determining step is the association of 
CYP2J2 and CPR when the N-terminus is truncated—as in CYP2J2tr. In this scenario, the 
association of the CYP2J2 and CPR would be occurring at a rate slower than any of the 
possible individual rates of the subsequent CYP reduction. However, for the full-length 
CYP2J2ﬂ, this association step is rapid, therefore the rate-determining step would still be the 
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electron transfer from CPR to CYP2J2—as shown before for the pre-incubation studies. This 
raises the possibility that rapid association in vivo may be possible for membrane-bound CYP 
and CPR via their hydrophobic N-termini. Our second hypothesis that explains the differences 
in the electron transfer kinetics between CYP2J2ﬂ and CYP2J2tr is that the conformations 
adopted immediately after association of CYP2J2 and CPR are less optimal for electron 
transfer in CYP2J2tr as compared to CYP2J2ﬂ. This difference implies that the N-terminus 
helps in docking the CYP2J2 with respect to CPR to aid in efﬁcient electron transfer. 
Thermodynamic data supports this hypothesis and shows that the Ks of binding of CYP2J2ﬂ 
and CYP2J2tr with CPR are of the same order of magnitude (Fig 3.5). In addition, our stopped 
flow data for association of CYP2J2tr and CPR show that even without the presence of the N-
terminus on CYP2J2, there is a rapid rate of association. The fact that the detected rate of protein 
association is similar to the fastest rate of electron transfer seen in these studies shows that the 
protein association data and the electron transfer data are in agreement. 
 
In summary, we show the N-terminus of CYP2J2 protein's importance in forming the CYP–
CPR complex to facilitate electron transfer and we also provide substantial evidence that the 
multiphasic kinetics arise from multiple conformations of the CYP2J2–CPR complex. 
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Chapter Figures and Tables 
 
 
 
 
 
 
 
 
 
FIG 3.1: CYP2J2 BINDING TO EBASTINE AND ARACHIDONIC ACID. The change in absorbance (ΔA) for ebastine (393–417 nm) and arachidonic 
acid (434–411 nm) was calculated for each titration and plotted against the corresponding substrate concentration (μM). (A) Ebastine was added 
incrementally from 0 to 80 μM. A single binding isotherm was applied to calculate the apparent Ks of CYP2J2tr which was calculated to be 8.2 ± 
1.3 μM. (B) Arachidonic acid was added incrementally from 0 to 120 μM. A single binding isotherm was applied to calculate the Ks of arachidonic 
acid binding to CYP2J2tr and was calculated to be 15.1 ± 0.6 μM. 
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FIG 3.2: ELECTRON TRANSFER KINETICS OF THE FORMATION OF FE(II)-CO PEAK AT 449 NM MONITORED USING STOPPED FLOW 
SPECTROSCOPY. (A) Three-dimensional plot of representative absorbance spectra from 0 to 1000 s following mixing of NADPH with a CYP2J2–
CPR pre-incubated complex. (B) Selected time points plotted (0.2, 2, 20, 200 and 1000 s) showing the absorbance changes over time. (C) 
Representative plot of changes in absorbance at 449 nm from 0 s to 200 s. Data points (circles) are overlaid with the line of best ﬁt (solid line) 
derived from a three-summed exponential kinetic equation in OriginLab. 
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FIG 3.3: SCHEMATIC OF CYP AND CPR IN LIPID BILAYER NANODISCS. The cyan represents the phospholipids, which have gold head 
groups. Blue represents the membrane scaffold protein encircling the lipid bilayers. This model was generated using Visual Molecular 
Dynamics (VMD) version 1.9.1. Coordinates for the CYP2J2 model (red) were obtained with a homology model created using 
Molecular Operating Environment (MOE) software. Coordinates for the CPR model (gray) were obtained from the Protein Data Bank. 
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FIG 3.4: ASSOCIATION-DEPENDENT ELECTRON TRANSFER KINETICS OF THE FORMATION OF FE(II)-CO PEAK AT 449 NM OVER TIME (100 S). 
Samples were prepared in the presence of 0.1% cholate without substrate. Data points (circles) are overlaid with the best ﬁt line (solid line) derived 
from a three-summed exponential kinetic equation in OriginLab. (A) CYP2J2tr reduction and (B) CYP2J2ﬂ reduction. 
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FIG 3.5: STEADY STATE TITRATIONS OF THE FULL-LENGTH CYP2J2FL AND TRUNCATED CYP2J2TR WITH CPR. CYP2J2 (0.5 μM) 
was prepared in 0.1 M phosphate buffer (7.4) with 0.1% Na cholate at 0.5 μM. CPR was added sequentially at concentrations from 0.05 to 5.0 μM. 
The difference spectra were derived and the change in absorbance was determined by subtracting absorbance at 390 nm from absorbance at 417 
nm. The Ks of binding were calculated by ﬁtting the data using a tight binding Morrison equation and were determined to be (A) 0.58 ± 0.14 μM 
for CYP2J2ﬂ and (B) 0.12 ± 0.06 μM for CYP2J2tr. 
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TABLE 3.1: THE RATE OF REDUCTION OF CYP2J2 PRE-INCUBATED WITH CPR 
Sample identity     
 
Rate (s-1)         
 
Amplitude (%)         
Protein   Substrate   k1   k2   k3   A1   A2   A3 
CYP2J2tr 
 
None 
 
0.55 ± 0.02 
 
  0.11 ± 0.02 
 
  0.018 ± 0.005 
 
42.2 ± 1.4 
 
37.5 ± 0.9 
 
20.4 ± 1.6 
CYP2J2tr 
 
AA 
 
0.47 ± 0.06 
 
0.068 ± 0.002* 
 
0.0067 ± 0.0018 
 
47.9 ± 3.5 
 
36.9 ± 1.8 
 
15.2 ± 1.7* 
CYP2J2tr 
 
Ebastine 
 
  1.8 ± 0.4* 
 
  0.17 ± 0.08 
 
  0.013 ± 0.002 
 
54.5 ± 1.0* 
 
27.2 ± 1.2* 
 
18.3 ± 1.5 
CYP2J2fl 
 
None 
 
0.69 ± 0.18 
 
0.061 ± 0.030 
 
0.0028 ± 0.0009 
 
51.5 ± 6.2 
 
17.4 ± 2.9 
 
31.1 ± 5.2 
CYP2J2fl 
 
AA 
 
  1.1 ± 0.2 
 
  0.11 ± 0.04 
 
0.0046 ± 0.0009 
 
50.8 ± 3.0 
 
22.6 ± 2.4 
 
26.6 ± 2.4 
CYP2J2fl   Ebastine     1.3 ± 0.2*     0.11 ± 0.02   0.0093 ± 0.0015*   49.8 ± 3.6   25.1 ± 5.2   25.1 ± 4.1 
All samples were prepared in 0.1% cholate with CPR at 6 mM and CYP at 2 M prior to mixing. Rate constants and corresponding amplitudes as a proportion of 100% are listed. 
Standard error is from multiple trials of each experiment. CYP2J2fl is CYP2J2 full-length with an intact N-terminus domain. CYP2J2tr is CYP2J2 truncated by removal of the N-
terminus membrane anchoring domain. AA= Arachidonic Acid. 
* Represents statistically significant value versus samples with no substrate (p < 0.05). 
       
 
 
 
 
 
 
  
47 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE 3.2: THE RATE OF REDUCTION OF CYP2J2TR NANODISCS PRE-INCUBATED WITH CPR 
Sample identity     
 
Rate (s-1)         
 
Amplitude (%)         
Protein   Substrate   k1   k2   k3   A1   A2   A3 
CYP2J2tr 
 
None 
 
0.40 ± 0.09 
 
0.043 ± 0.005 
 
0.0040 ± 0.0001 
 
26.9 ± 1.7 
 
36.2 ± 0.7 
 
37.0 ± 2.1 
CYP2J2tr 
 
AA 
 
0.31 ± 0.02 
 
0.042 ± 0.007 
 
0.0043 ± 0.0003 
 
26.1 ± 2.3 
 
28.6 ± 11.5 
 
45.3 ± 13.8 
CYP2J2tr   Ebastine   0.45 ± 0.02 
 
0.049 ± 0.002 
 
0.0048 ± 0.0001*   34.9 ± 1.0*   31.4 ± 0.6*   33.7 ± 0.4 
* Represents statistically significant value versus samples with no substrate (p < 0.05). 
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TABLE 3.3: THE ASSOCIATION-DEPENDENT RATE OF REDUCTION OF CYP2J2TR AND CYP2J2FL WITH CPR 
Sample identity     
 
Rate (s-1)         
 
Amplitude (%)         
Protein   Substrate   k1   k2   k3   A1   A2   A3 
CYP2J2tr 
 
None 
 
0.0020 ± 0.0001 
 
x 
 
x 
 
100 
 
x 
 
x 
CYP2J2tr 
 
AA 
 
0.0024 ± 0.0002 
 
x 
 
x 
 
100 
 
x 
 
x 
CYP2J2tr 
 
Ebastine 
 
 0.0071 ± 0.0003* 
 
x 
 
x 
 
100 
 
x 
 
x 
CYP2J2fl 
 
None 
 
0.42 ± 0.08 
 
0.018 ± 0.001 
 
0.0039 ± 0.0004 
 
13.3 ± 2.5 
 
53.1 ± 5.5 
 
33.6 ± 4.5 
CYP2J2fl 
 
AA 
 
0.45 ± 0.15 
 
0.014 ± 0.0004 
 
0.0027 ± 0.0007 
 
4.09 ± 1.12* 
 
70.8 ± 2.2* 
 
25.1 ± 1.8 
CYP2J2fl   Ebastine    1.0 ± 0.3*   0.017 ± 0.002   0.0032 ± 0.0011   12.8 ± 3.5   74.6 ± 2.1*   12.6 ± 2.8* 
* Represents statistically significant value versus samples with no substrate (p < 0.05). 
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FIG 3.6: ASSOCIATION-DEPENDENT KINETICS OF THE FORMATION OF A CYP2J2-CPR COMPLEX. Samples were prepared in the presence of 
0.1% cholate without substrate. Data points (circles) are overlaid with the best ﬁt line (solid line) derived from a three-summed exponential kinetic 
equation in OriginLab. CYP2J2tr association with CPR was monitored by the difference spectrum between 390 nm and 417 nm. 
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FIG 3.7: PRE-INCUBATION STUDIES—KINETICS OF ELECTRON TRANSFER TO CYP2J2 WHEN INCUBATED IN THE SAME SYRINGE WITH 
CPR. Shown are representative data of experiments where CYP2J2 and CPR were pre-incubated in the same syringe and rapidly mixed with an 
NADPH solution saturated with carbon monoxide. The absorbance at 449 nm versus time is fitted to a rate equation and the rate constant and 
amplitudes were calculated as described in the Materials and Methods. The residual plot is a measure of closeness of fit and plotted for each 
respective condition below the kinetics graph. The kinetics of the full-length construct, CYP2J2fl, was examined in (A) the absence of substrate, 
(B) saturating concentrations of arachidonic acid, and (C) saturating concentrations of ebastine. Similarly, the kinetics of the truncated construct, 
CYP2J2tr, was examined in the (D) absence of substrate, (E) presence of saturating arachidonic acid, and (F) presence of saturating concentrations 
of ebastine.  
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FIG 3.8: PHASE KINETICS OF ELECTRON TRANSFER OF CYP2J2 WHEN INCORPORATED WITH CPR INTO NANODISCS. A syringe containing 
CYP2J2tr-Nanodiscs pre-incubated with CPR was rapidly mixed with a syringe containing carbon monoxide and NADPH. The rate of electron 
transfer was measured by monitoring the absorbance at 449 nm and plotted against time. The rates and amplitudes were calculated as described in 
the Materials and Methods. The residual plot is a measure of closeness of fit and plotted for each respective condition below each kinetics plot. 
The kinetics of the full-length construct, CYP2J2tr, was examined in (A) the absence of substrate, (B) saturating concentrations of arachidonic 
acid, and (C) saturating concentrations of ebastine. 
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FIG 3.9: ASSOCIATION-DEPENDENT STUDIES—KINETICS OF ELECTRON TRANSFER TO CYP2J2 WHEN SEPARATE FROM A SYRINGE 
CONTAINING CPR AND CARBON MONOXIDE. Separate syringes were rapidly mixed and the absorbance at 449 nm versus time was fitted to a 
rate equation and the values rate constant and amplitudes were calculated as described in the Materials and Methods. The residual plot is a 
measure of closeness of fit and plotted for each respective condition below each kinetics plot. The kinetics of the full-length construct, CYP2J2fl, 
was examined in the (A) the absence of substrate, (B) saturating concentrations of arachidonic acid, and (C) saturating concentrations of ebastine. 
Similarly, the kinetics of the truncated construct, CYP2J2tr, was examined in the (D) absence of substrate, (E) presence of saturating 
concentrations of arachidonic acid, and (F) presence of saturating concentrations of ebastine. 
 
53 
CHAPTER 4: ACTIVE SITE MUTATIONS OF 
 CYP5A1 THAT AFFECT CATALYSIS
2
 
 
Abstract 
 
Thromboxane synthase (CYP5A1) is a non-classical cytochrome P450 (CYP) expressed in human 
platelets that mediates vascular homeostasis by producing thromboxane A2 (TXA2) through the 
isomerization of prostaglandin H2 (PGH2). A homology alignment of CYP5A1 with human CYPs 
indicates that a highly conserved I-helix threonine residue is occupied by an isoleucine at position 346 in 
CYP5A1. We find that reverse-engineering CYP5A1 to contain either threonine or serine in this position 
dramatically increases TXA2 formation. Interestingly, the levels of malondialdehyde (MDA), a homolytic 
fragmentation product of PGH2 formed via a pathway independent of TXA2 formation, remain constant. 
Furthermore, spectral analysis using two PGH2 substrate analogs supports the observed activity changes 
in the hydroxyl-containing mutants. The more constrained active site of the I346T mutant displays altered 
PGH2 substrate analog binding properties. Together these studies provide new mechanistic insights into 
CYP5A1 mediated isomerization of PGH2 with respect to a critical active site residue. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
____________________________________ 
2
This chapter appeared in its entirety in Biophysical Chemistry. Meling, D.D., Zelasko, S., Kambalyal, A., Roy, J., 
and Das, A., 2015. “Functional Role of the Conserved I-helix Residue I346 in CYP5A1-Nanodiscs.” 200-201:34-40 
(102). This article is reprinted with permission of the publisher. This chapter has minor changes and contains 
additional material not found in the original publication.  
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Introduction 
 
Cytochrome P450s (CYPs) are heme-containing enzymes that catalyze numerous oxidative 
reactions in nature including the hydroxylation and epoxidation of alkenes, as well as less 
commonly, the isomerization of endoperoxide-containing substrates (103). In order to catalyze 
hydroxylation or epoxidation reactions, classical Type I and II CYPs shuttle through heme-
oxygen reactive intermediates such as iron-hydroperoxo and iron-oxenoid species (Fig 4.1). This 
hydroperoxo intermediate of the heme is thought to be stabilized by the hydroxyl group of a 
highly conserved threonine residue in the I-helix, positioned on the distal side of the heme active 
site (Figs 4.1 and 4.2) (104, 105). This residue mediates the formation of an appropriate 
hydrogen bonding network, either directly by the threonine group or by the positioning of a 
water molecule within the active site (105). Previous mutagenesis studies on this threonine 
residue in other CYPs have shown that mutating this residue significantly impacts enzyme 
function. The alteration of this residue presumably destabilizes the iron-hydroperoxo 
intermediate, leading to a decrease in formation of the native hydroxylated or epoxygenated 
product and an increase in the production of reactive oxygen species (105-109). The hydrogen 
bonding network facilitated by this threonine is also important in many CYPs for two proton 
transfer steps that allow the heme intermediate to transition from an iron-peroxo to an iron-
hydroperoxo and then to an iron-oxenoid species, eventually leading to the epoxidation or 
hydroxylation of the substrate (9).  
 
Interestingly, a sequence homology alignment of the known human CYPs shows that there are a 
few human CYPs that lack this conserved threonine and instead contain isoleucine or asparagine 
(Fig 4.2). These CYPs are either isomerases (e.g., CYP5A1, CYP8A1) instead of typical 
hydroxylases or they have unknown functions (e.g., CYP20A1, CYP39A). Prostacyclin synthase 
(CYP8A1) has an asparagine (N287) residue instead of threonine and the CYP8A1 crystal 
structure suggests that the capacity to form a hydrogen-bond network through the asparagine 
remains (33). In contrast, an isoleucine residue is present in two human CYPs, thromboxane 
synthase (CYP5A1) and the orphan CYP20A1, as well as in allene oxide synthase (CYP74A1) 
from the plant Arabidopsis thaliana (110, 111). Isoleucine is incapable of participating in a 
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hydrogen bonding network and the purpose of this active site residue in product formation has 
not been thoroughly examined. 
 
Of the two human CYPs with an isoleucine instead of a threonine, CYP5A1 has been studied 
more extensively and is known to mediate cardiovascular homeostasis by generating 
thromboxane A2 (TXA2). CYP5A1 is expressed in platelets (34) and converts prostaglandin H2 
(PGH2) either into TXA2 via an isomerization of the endoperoxide bond or into two 
fragmentation products, 12-L-hydroxy-5,8,10-heptadecatrienoic acid (HHT) and 
malondialdehyde (MDA) (Fig 4.3) (35, 112). 
 
HHT is an endogenous ligand for the leukotriene B4 receptor BLT2 which is implicated in 
allergic airway inflammation (113). The precise role of MDA remains undetermined, however, it 
has been found to form adducts with proteins, phospholipids (114), and DNA, particularly in 
atherosclerotic lesions (115). Homeostatic imbalances in CYP5A1 that lead to the over-
production of TXA2 have been implicated in the development of several major disorders (116-
119). Owing to the unique biochemical nature and physiological significance of CYP5A1, it is 
important to better understand the mechanistic details of this enzyme with respect to this specific 
residue Ile346. 
 
In this work, we have reverse-engineered the native isoleucine 346 to threonine in CYP5A1 in 
order to understand its role in substrate binding and product formation. We have also mutated 
this isoleucine 346 to serine, a smaller hydroxyl-containing residue, to examine the spatial 
constraints of the substrate orientation within the enzyme active site. Here we describe the 
biochemical characteristics of these mutants and show that the introduction of a hydroxyl-
containing residue significantly influences native CYP5A1 function. All studies were performed 
using CYP5A1 in Nanodiscs (i.e., nanoscale lipid bilayers) that stabilize the enzyme in a native 
membrane environment. This produces reproducible and cleaner spectroscopic data and provides 
a native-like membrane environment to evaluate the enzyme function (38, 87, 88, 120-123). 
Hence, this work provides insights into the role of the key active site residue 346 in thromboxane 
synthase function within a native membrane environment with respect to substrate isomerization 
and substrate analog binding.  
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Materials and Methods 
 
Materials 
 
The human CYP5A1 gene was obtained from Origene. PCR reagents were purchased from New 
England Biolabs. Molecular biology enzymes and E. coli DH5α were purchased from Invitrogen. 
Plasmid DNA was purified using a Qiagen Gel Extraction kit. Ampicillin (Amp), arabinose, 
chloramphenicol (Chlr), isopropyl β-D-1-thiogalactopyranoside (IPTG), and Ni-NTA resin were 
bought from Gold Biotechnology. δ-Aminolevulinic acid (δ-ALA) was purchased from Frontier 
Scientific. 1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (POPC) was purchased from 
Avanti Polar Lipids. PGH2, 9,11-dideoxy-9α,11α-epoxymethano Prostaglandin F2α (U44069), 
and 9,11-dideoxy-9α,11α-methanoepoxy Prostaglandin F2α (U46619) were purchased from 
Cayman Chemicals. NADPH was purchased from P212121.com. The TXB2 ELISA kit was 
purchased from Oxford Biomedical Research.  
 
Protein engineering of CYP5A1 
 
The CYP5A1 gene (Origene) was cloned into the pAr5 (modified pCWOri+) plasmid using the 
NdeI and XbaI restriction fragment sites located downstream of the IPTG-inducible tac promoter 
with Amp resistance. The CYP5A1 protein was modified by truncating the first 29 amino acids, 
incorporating an N-terminal hydrophilic sequence MAKKTSS, and a C-terminal 6-histidine tag. 
The plasmids were amplified and purified using a Qiagen Plasmid mini-prep kit (Valencia, CA). 
The I346T and I346S mutations were made using forward primers containing single nucleotide 
substitutions at residue 346. The reverse primer was phosphorylated with T4 polynucleotide 
kinase (New England Biolabs). The forward and reverse primer sequences are listed in Fig 4.4. 
The PCR reaction consisted of 1 µM of forward and reverse primers in HF reaction buffer (New 
England Biolabs) containing 50 pg/µL CYP5A1-containg plasmid, 200 µM dNTPs, 5% DMSO, 
and Phusion DNA polymerase (10 U/mL). The PCR thermocycler was set to 95 ℃ for 3 min, 20 
cycles (95 ℃ for 30 s, 65 ℃ for 30 s), and then 72 ℃ for 4 min. Chemically competent DH5α 
cells were transformed by heat shock at 42 ℃ for 45 s, then set on ice. The addition of 1 mL of 
warm Super Optimal Broth (SOC) media was followed by shaking (250 rpm) at 37 ℃ for 1 hr. 
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Cells were plated on LB Amp in order to screen for the desired mutant plasmid. The mutant 
dsDNA was confirmed by DNA sequencing. 
 
Expression of CYP5A1 mutants 
 
The expression of the CYP5A1 mutants was performed as previously described (38, 40, 124). 
 
Carbon monoxide binding assay 
 
The heme content of the purified CYP5A1 protein was analyzed using UV-vis spectroscropy 
(Agilent Technologies, Santa, Clara CA) as previously described (38). 
 
PGH2 assay and TXB2 quantification 
 
The enzymatic activity of each protein was determined by quantifying TXB2 and MDA 
formation using a Cary 300 UV-vis spectrometer (Agilent Technologies) in scan mode and a 
competitive binding ELISA assay read using a microplate reader at 650 nm, respectively, as 
described previously (38, 125). 
 
Equilibrium binding of CYP5A1-ND with substrate analog 
 
The binding of substrate analogs U44069 and U46619 to CYP5A1-ND mutants were performed 
by spectroscopic titrations with each analog. First, each CYP5A1-ND mutant (WT, I346T, and 
I346S) at final concentrations of 0.5 μM in potassium phosphate buffer was incubated with 
increasing concentrations of U44069 or U46619, ranging from final concentrations of 0 to 100 
μM dissolved in ethanol such that the final ethanol concentration did not exceed 1.5%. The 
absorbance readings were measured using a Cary 300 UV-vis spectrometer (Agilent 
Technologies) in full scan mode. The data was analyzed using MATLAB by taking a difference 
spectrum of the absorbance peaks and troughs at wavelengths of 426 and 409 nm for U44069 
and 418 and 395 nm for U46619, then plotting absorbance change versus analog concentration in 
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Origin Lab (Origin Lab, Northampton, MA). The data was fit using the Hill equation (Equation 
4.1). 
 
∆𝐴 =
𝐴𝑚𝑎𝑥 ∙ 𝑆
𝑛
𝐾𝑠
𝑛 +  𝑆𝑛
    (Equation 4.1) 
 
In Equation 4.1, ∆𝐴 is the absorbance difference at 426 and 409 nm for U44069 and 418 and 395 
nm for U46619, Amax is the amplitude corresponding to maximal spin shift, Ks is the spectral 
dissociation constant, S is the substrate concentration, and n is the Hill coefficient. The binding 
data fit closely to n=1. Therefore, for final fitting a single binding isotherm was used. The 
calculated spectral binding constants are averages of two independent experiments. 
 
Assembly of CYP5A1-nanodiscs 
 
CYP5A1-ND were assembled as previously described (38, 40, 124) from a mixture of CYP5A1, 
membrane scaffold protein (MSPD1(-)), cholate, and POPC lipids by removing the detergents 
using Amberlite® (126, 127) and cleaving the histidine tag in MSP1D1 (128).  
 
Liquid chromatography-mass spectrophotometric analysis 
 
PGH2 (20 µM) was added to CYP5A1 suspended in Tris-Cl buffer (200 nM, pH 8.0). MDA 
formation was monitored spectroscopically at 268 nm for 3 min. This reaction was quenched 
with one volume of ethyl acetate and the organic layer was removed and re-extracted with 
another volume of ethyl acetate. The organic layers were dried under N2 gas and resuspended in 
ethanol. The products were monitored by an LC-MS system that consisted of a Waters Alliance 
2795 analytical high-performance-liquid-chromatography separation module (Waters, Milford, 
MA) coupled to an electrospray ionization mass spectrometer (Waters Quattro Ultima, Waters, 
Milford, MA) operated in negative ion mode. The sample was analyzed using a reverse-phase 
C18, 1.3 Å, 2.1 mm x 20 mm and 2.5 µm pore size column (Waters, Milford, MA) at a flow rate 
of 0.2 mL/min. The solvent system was composed of two solutions: solvent A (95% H2O, 5% 
acetonitrile (ACN) and 0.1% formic acid (FA)) and solvent B (5% H2O and 95% ACN, and 
59 
0.1% FA). The 40 min gradient LC separation consisted of a linear gradient 35% → 85% solvent 
B.  
 
Molecular Operating Environment modeling and ligand docking 
 
The models of CYP5A1 WT, I346T, and I346S were developed using homology modeling in 
PHYRE2 (129). An open conformation of the CYP5A1 model was generated and used for 
subsequent ligand binding studies in Molecular Operating Environment software (MOE) 
(Chemical Computing Group Inc., Montreal, QC, Canada). Docking was performed using the 
Dock module of MOE. The activity site cavity was identified near the heme in the homology 
model of each protein. The ligand PGH2 was prepared in the MOE Molecular Editor module and 
was docked into the cavities to generate possible ligand conformations. The default 
nonstochastic Triangle Matcher placement method was used as well as molecular mechanics 
refinement. Ten models with the ligand bound within the cavity with the endoperoxide oxygens 
near the heme (less than 7 Å) were generated and chosen for energy minimization. The models 
were verified by review of the Ramachandran torsion angles of amino acid residues. The energy 
minimized CYP5A1 models with the substrate docked were used to measure the average 
distances from the heme iron to the hydroxyl group of the mutated 346 residue and to the 
endoperoxide oxygens of the substrate. Interaction energies which indicate the change of free 
energy when the substrate is bound, were energetically favorable were compared for all three 
mutants. 
 
Equilibrium binding of CYP5A1-ND with cytochrome P450 reductase 
 
The binding of cytochrome P450 reductase (CPR) to CYP5A1-ND mutants was performed by 
co-incubating CYP5A1-ND with increasing concentrations of CPR. First, CYP5A1-ND at a final 
concentration of 0.5 μM in potassium phosphate buffer was incubated with concentrations of 
CPR ranging from final concentrations of 0.05 to 4.5 μM. Following each addition of CPR, the 
mixture was incubated for 15 minutes at 37 °C to allow sufficient time for binding to occur. The 
absorbance readings were measure using a Cary 300 UV-vis spectrometer (Agilent 
Technologies). The data was analyzed using MATLAB by taking a difference spectrum of the 
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absorbance at wavelengths of 417 nm and 390 nm, then plotting the absorbance change versus 
analog concentration in Origin Lab (Origin Lab, Northampton, MA). Prior to fitting, the 
absorbance changes caused by CPR interacting with Nanodiscs alone were subtracted from the 
data. The data was fit using the Hill equation (Equation 4.1). 
 
Hydrogen peroxide assay 
 
The levels of H2O2 formation were measured by an Amplex Red © and horseradish peroxidase 
detection assay using a Gemini™ EM Fluorescence Microplate Reader (Molecular Devices) and 
analyzed using SoftMax® Pro Microplate Data Acquisition & Analysis Software (130). The 
Amplex Red© reagent was prepared by first dissolving the reagent in DMSO to a concentration 
of 1.33 mg/mL and then diluting this solution into 20 mL of ice-cold dipotassium phosphate 
buffer (50 mM, pH 7.8). The reagent was kept in the dark prior to use. The assay was performed 
by mixing 25 μL of the Amplex Red© reagent with 50 μL of the NADPH (100 μM) reaction 
mixture containing CYP5A1-ND and CPR. Next 25 μL of horseradish peroxidase (50 μg/mL in 
ice-cold dipotassium phosphate buffer 50 mM, pH 7.8) was immediately added, and the reaction 
was incubated for 45 sec at room temperature. The fluorescence excitation wavelength was 520 
nm and the emission wavelength was measured at 620 nm. Quantification was carried out using a 
standard curve of known H2O2 concentrations.  
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Results 
 
Expression of CYP5A1 mutants and incorporation into Nanodiscs 
 
We mutated the isoleucine at position 346 of CYP5A1 to threonine to investigate how a 
hydroxyl-containing residue near the catalytic heme would affect the native CYP5A1 reactions. 
This position was also mutated to serine in order to examine the potential influence of residue 
size on the binding and stabilization of the substrate within the enzyme active site. The mutations 
were carried out using site-directed mutagenesis. The proteins were purified and incorporated 
into Nanodiscs as described in the Methods and Materials section. Protein purification yields are 
listed in Table 4.1. 
 
Metabolism of PGH2 by CYP5A1 
 
CYP5A1 converts PGH2 into the major physiological metabolite TXA2, as well as MDA and 
HHT. TXA2 rapidly hydrolyzes non-enzymatically to TXB2 (Fig 4.3). The enzymatic activity of 
CYP5A1 and the mutants was determined by quantifying the TXB2 and MDA formation 
following incubation of CYP5A1-Nanodiscs (CYP5A1-ND) with PGH2. The amount of TXB2 
formed via Pathway A was determined using an ELISA-based detection method and MDA was 
monitored spectroscopically at 268 nm (Fig 4.5). Mechanistically, MDA and HHT are formed in 
an equimolar ratio, hence, only MDA was monitored to track pathway B (Fig 4.3). 
Quantification of MDA and TXB2 revealed that the mutation from isoleucine to a hydroxyl-
containing threonine or serine residue caused an approximately two-fold increase in TXB2 
production. The I346T mutant produced 239% and the I346S mutant produced 161% TXB2, 
relative to wild-type. Interestingly, MDA and HHT formation, which was at a higher overall rate 
than TXB2 production, remained statistically constant for wild-type and I346 mutants of 
CYP5A1-ND. Lipids in the Nanodiscs were 100% POPC, which allow statistically the same 
amount of TXB2 production as a more physiological lipid mixture of POPC/POPE/POPS 
(53:40:7) (38). Additionally, the product ratio of the mutants was unaffected by the use of 
Nanodiscs (data not shown) and the Nanodisc system yielded reproducible data. The rate of 
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conversion of PGH2 into TXA2 was confirmed with the LC-MS experiments. These similar rates 
of increase in TXB2 production were 165% for I346T and 162% for I346S. 
 
Spectral Characterization 
 
The oxidized spectra of the CYP5A1-ND wild-type, I346T, and I346S protein had Soret peaks at 
417 nm, 417 nm, and 419 nm, respectively, with the α and β bands (Q-bands) appearing near 536 
nm and 570 nm, respectively. Determination of the heme content and assessment of protein 
folding was obtained from a dithionite-reduced CO bound spectrum of the heme proteins (Table 
4.2). The Fe(II) CO-bound complex formed showed a 452 nm and 451 nm peak in the wild-type 
and I346T mutant proteins, respectively. The I346S mutant showed a red-shifted CO-bound 
spectrum at 454 nm, indicating the active site had become more polar or that the hydroxyl of the 
serine residue may interact with the heme group (Fig 4.6) (131, 132).  
 
Equilibrium binding studies of CYP5A1 with substrate analogs 
 
We further performed spectral titrations using two analogs of the native substrate PGH2, U44069 
and U46619. The analog 9,11-epoxymethano PGH2 (U44069) has an oxygen atom at the C9 
position, while the analog 11,9-epoxymethano PGH2 (U46619) has an oxygen atom at the C11 
position. In both cases, an oxygen of the endoperoxide bond is replaced by a methylene group 
making a CH2-O bond instead of an O-O bond (Figs 4.3 and 4.7). 
 
There were some interesting differences in the binding of the substrate analogs to the I346T and 
I346S mutants. The binding of U44069 to wild-type CYP5A1-ND that is thought to reflect 
native PGH2 binding showed a typical trough near 426 nm and a peak near 409 nm, as expected 
(38). The spectral dissociation constant (Kd) for binding of U44069 to wild-type CYP5A1-ND is 
6.0 ± 3.0 μM, to the I346T mutant is 5.0 ± 0.3 μM, and to the I346S mutant is 4.0 ± 1.8 μM. The 
UV-vis spectral wavelength shifts due to U44069 binding were nearly constant for all mutants 
(Table 4.2). While spectral perturbations seen with respect to binding U44069 were not 
significant, those observed for the binding of U46619 with the mutants were significant. 
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The difference spectrum of each CYP5A1-ND bound to U46619 shows a characteristic high-spin 
state based on a peak shift to around 390 nm, which suggests the C9 methylene group of the 
analog is near the CYP-bound heme. Interestingly, the I346S mutant of U46619-bound 
CYP5A1-ND produced red-shifted UV-vis spectral shifts of 8.5 ± 0.7 nm compared to 4 ± 0.0 
nm and 3 ± 0.0 nm for the I346T mutant and wild-type CYP5A1-ND, respectively (Table 4.2 
and Fig 4.7) (38). There is significant decrease in binding affinity with U46619 and the I346T 
mutant (Kd is 15 ± 3 μM) (Table 4.2) compared to the I346S mutant. It is likely that the smaller 
cavity near the active site in the I346T versus the I346S mutant appears to accommodate U46619 
to a lesser extent, leading to lower binding affinity in the I346T mutant. 
 
LC-MS analysis of product formation by mutant CYP5A1 
 
We determined the product profiles of the wild-type and the threonine and serine mutants of 
CYP5A1 following incubation with PGH2 using LC-MS as described in the Methods and 
Materials section. No novel products were detected in the mutant proteins beyond those 
quantified using UV-vis spectroscopy and ELISA. 
 
Equilibrium binding studies of CYP5A1 with CPR 
 
We directly measured the binding of CYP5A1 with CPR. The spectral titration studies indicate 
that CYP5A1-WT does bind CPR with a Ks equal to 0.36 ± 0.16 μM (Fig 4.8). The mutants also 
bind CPR with similar affinity. This demonstrates that, although there is no need for electron 
transfer, CYP5A1 retains the capacity to interact with CPR. Previously, Hecker and coworkers 
have also shown that CYP5A1 can catalyze a hydroxylation reaction of PGH2 when the enzyme 
is reduced by iodosylbenzene under non-physiological conditions (133). We did not observe any 
electron transfer activity that will lead to the reduction of CYP5A1 by NADPH via CPR in the 
presence of carbon monoxide (data not shown). Next, we measured NADPH oxidation in the 
presence and absence of substrate. We did not see any changes in the NADPH oxidation rate due 
to either the mutations or the presence of U44069 (data not shown). Therefore no electron 
transfer from NADPH to CYP5A1 via CPR was observed in the presence or absence of 
substrate. 
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Rate of hydrogen peroxide generation from CPR-CYP5A1-ND system 
 
A potential product of the CYP-CPR electron transfer is generation of reactive oxygen species 
(134, 135) also termed as uncoupling reactions. Uncoupling in isomerases such as CYP5A1 has 
not been previously investigated. Hence, we further investigated the use of NADPH by the 
CYP5A1-ND-CPR system to form H2O2. We measured the levels of H2O2 using a sensitive 
Amplex Red fluorescence detection method (130). In these incubations, CYP5A1 alone with 
NADPH did not produce H2O2 levels above baseline levels (Fig 4.9). However, CPR itself 
generated H2O2 when interacting with NADPH. We observed an average of an 80% decrease in 
H2O2 production from the CPR and CYP5A1 incubation reactions, as compared to incubations of 
CPR alone, revealing that the interaction of CYP5A1 with CPR prevents the production of 
reactive oxygen species by CPR. This confirms our binding studies that CYP5A1 and CPR 
interact with each other. 
 
In classical hydroxylating CYPs, the conserved threonine residue has been shown to stabilize the 
iron-hydroperoxo intermediate, diminishing H2O2 production (105, 107, 136). To determine 
whether reverse engineering the isoleucine of CYP5A1 to a hydroxyl-containing residue has 
altered the CYP’s capacity to generate reactive oxygen species, we evaluated the H2O2 levels of 
the wild-type and the mutants co-incubated with CPR. The production of H2O2 trended higher in 
the mutants but was statistically the same for each construct.  
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Discussion 
 
The role of the isoleucine residue in CYP5A1 
 
The vast majority of CYPs contain a highly conserved threonine residue positioned on the distal 
side of the heme active site, however, the role of this residue is variable (104, 105). In many 
classical CYPs, the threonine hydroxyl group is believed to be involved in hydrogen-binding and 
proton delivery to the heme-bound oxygen during reactions (107, 137). In CYP8A1, the 
conserved I-helix threonine is replaced with an asparagine residue that is capable of forming 
hydrogen-binding networks through the available nitrogens (33). In contrast, CYP5A1 contains 
an isoleucine in place of this conserved threonine (34, 35). It is important to note that the close 
placement of this residue on the distal side of the heme active site can significantly influence 
native catalytic function. Therefore, the introduction of a hydroxyl near the heme may change the 
capacity of CYP5A1 towards radical stabilization. In absence of a crystal structure for CYP5A1, 
we prepared a Molecular Operating Environment (MOE) model of CYP5A1 bound to PGH2 that 
indicated that both isoleucine and the hydroxyl groups of threonine and serine are within 4 to 6 Å 
of the heme active site (Fig 4.10 and Fig 4.11). 
 
Mutation of isoleucine 346 to hydroxyl-containing residues increased native product formation 
of TXA2, confirming the influence of this residue position on CYP5A1 catalysis (138). Excess 
TXA2 is detrimental to cardiovascular health, thus this naturally occurring I346 residue may 
deviate from the conserved hydrogen-bonding residues in order to attenuate TXA2 levels in vivo. 
 
Mechanistic interpretation of the increase of thromboxane formation in I346T and I346S mutants 
 
From a mechanistic standpoint, the isomerization of PGH2 by CYP5A1 has been proposed to 
follow the Fe(III)-porphyrin pi-cation radical route that involves a bifurcation of a key 
intermediate into two different pathways leading to separate products (139) (Fig 4.3). In pathway 
A, PGH2 is converted to TXA2 and in pathway B, PGH2 is fragmented to MDA and HHT (Fig 
4.3). The PGH2 endoperoxide consists of two oxygens attached to carbons at positions C11 and 
C9. The oxygen attached at the C9 position interacts with heme at the active site (Fig 4.3) while 
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the oxygen attached at the C11 position forms the carbonyl group in the intermediates preceding 
product formation. We hypothesize that this oxygen attached at the C11 position is stabilized by 
hydrogen bonding in the I346T and I346S mutants. This stabilization would favor the cyclization 
of the intermediate leading to TXA2 formation, but has no effect on the fragmentation of this 
intermediate to form MDA and HHT. Evidence to support this hypothesis stems from the 
observation that upon binding U46619, in which the oxygen attached to the C11 carbon is 
proposed to be near the hydroxyl of the threonine or serine residue in the mutated protein, the 
Soret peak shifts by as much as 8.5 ± 0.7 nm for the I346S mutant. Interestingly, no such spectral 
shifts were observed using the U44069 where a –CH2– group replaces the C11 oxygen in 
U46619 (38). Additionally, the increased polarity of the mutant active sites due to the presence 
of a hydroxyl group may in general facilitate the electron transfer from the PGH2 intermediate to 
the heme moiety as a part of TXA2 formation. However, this does not explain the observed 
spectral changes discussed above. 
 
I346S vs. I346T, the role of the smaller residue 
 
We observed that the I346S mutant shows an 8.5 ± 0.7 nm wavelength shift on binding U46619 
(Table 4.2 and Fig 4.7). Moreover, Fe(II)-CO-bound spectrum is more red-shifted for the I346S 
mutant suggesting a change in the electronic environment of the heme due to the orientation of 
the polar serine group (131, 132). When threonine is changed to serine at this position in other 
CYPs, there is a precedent for a wider range of products being formed. For instance, a change in 
substrate orientation and specificity was observed when the conserved T303 of CYP2E1 was 
mutated to serine, along with a change from high-spin to mixed-spin in the ferric absorption 
spectrum (140). This is presumably due to the greater freedom of movement of the substrate. In 
our studies we did not detect any additional products using LC-MS, however, the I346S mutant 
did display altered activity and more extreme spectral characteristics from those of the wild-type 
and I346T mutant. 
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Significance of CYP5A1-CPR interaction and hydrogen peroxide production 
 
The effects of the observed interaction of CYP5A1 and CPR may have significance in vivo in 
human platelets. Previous studies have shown that CYP5A1 is the predominant P450 expressed 
in platelets at 23 times higher than all other CYPs combined (37), which is not surprising due its 
role in production of thromboxane, an important molecule for platelet aggregation. These studies 
also showed that CYP5A1 is expressed at a rate five times higher than CPR. The interaction of 
these proteins may have only a slight direct effect on the rate at which CYP5A1 produces 
thromboxane because the level of CPR is much lower. In contrast, the high ratio of CYP5A1 to 
CPR may have a significant impact on the hydrogen peroxide producing activity of CPR. In our 
experiments we saw a significant decrease in the hydrogen peroxide production when the 
proteins were co-incubated. The amount of inhibition trended toward being slightly different 
with the I346T and I346S mutants near the heme, thus indicating the added hydroxyl group may 
be in close enough proximity to CPR to affect this reaction. This interaction may be less transient 
than other CYP-CPR interactions due to the absence of electron transfer from CPR, and this may 
affect the movement of the domains of CPR. When bound to CYP5A1, CPR may be incapable of 
transferring electrons from its FAD domain to the H2O2-producing FMN domain, which would 
therefore decrease the reactive oxygen generation (141, 142). H2O2 production might also be 
blocked since the FMN domain would not be exposed to dissolved oxygen as it normally would 
be during electron transfer from the FAD domain (143). Since electron transfer to the CYP5A1 
heme cannot occur upon CYP-CPR binding, the FMN domain may remain at the CYP interface 
and thus be less able to bind oxygen or water, leading to lower reactive oxygen species 
production. There is potential physiological significance to this inhibition because hydrogen 
peroxide is known to stimulate the release of arachidonic acid from the cellular membrane (144). 
As arachidonic acid is a direct precursor to PGH2, CYP5A1 may play a role in limiting the 
availability of the substrate it needs for promoting platelet aggregation. 
 
Summary 
 
In summary, in this paper we uncover two new aspects of CYP5A1 function. Firstly, we reverse-
engineered the native isoleucine in CYP5A1 I-helix to the conserved threonine found in classical 
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CYPs to understand the role of this residue in product formation by CYP5A1. Upon mutation of 
I346 to threonine we observed a 239% increase in thromboxane formation while MDA and HHT 
formation remained almost the same. Excess thromboxane is detrimental to cardiovascular 
health, thus this naturally occurring I346 residue might help in keeping the levels of 
thromboxane lower in the platelets in the human body. In addition, we mutated this I-helix 
residue to serine, a smaller hydroxyl-containing residue, in order to gain a better understanding 
of the spatial constraints of the active site, polarity of this residue, and substrate orientation. 
Again we saw an increase in the production of thromboxane without any concomitant increase in 
MDA or HHT. Based on spectral characterizations, we hypothesized that the selective increase 
in the production of thromboxane is due to stabilization of the C11 oxygen of the carbonyl in the 
intermediate by hydrogen-bonding interactions between the hydroxyl moiety of threonine and 
with the oxygen atom at C11 of the substrate PGH2. The hydroxyl-containing residue selectively 
stabilizes the reaction pathway leading to TXA2 formation, but would not alter the MDA and 
HHT fragmentation pathway. Evidence to support this hypothesis comes from the observation 
that the binding of U46619, which only has an oxygen bound at the C11 position, to the 
threonine and serine mutants significantly perturbs their Sorets.  
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Chapter Figures and Tables 
 
 
FIG 4.1: CATALYTIC CYTOCHROME P450 REACTION CYCLE. Here is shown the non-classical P450 reaction cycle of CYP5A1 and CYP8A1 in 
the context of a classical P450 reaction cycle (10).  
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FIG 4.2: SEQUENCE ALIGNMENT OF THE KNOWN HUMAN CYTOCHROME P450S AND AT-AOS. The alignment of the amino acid sequences of all 
known human P450s and Arabidopsis thaliana allene oxide synthase (CYP74A1) was determined using CLUSTALW with standard settings. 
Sequences are shown from amino acids 339 to 353, based on CYP5A1 numbering. Yellow highlights the conserved I-Helix threonine at position 
346. Green indicates the isoleucine variant. Blue highlights the asparagine variant.  
71 
 
 
 
 
 
 
 
 
 
 
 
FIG 4.3: MECHANISM OF TXA2, MDA, AND HHT FORMATION BY CYP5A1. The proposed mechanism of TXA2 formation followed by non-
enzymatic hydrolysis to form TXB2 is shown to follow pathway A (139). Two fragmentation products (MDA and HHT) form via pathway B 
(139). The boxed intermediate that precedes TXA2 formation is likely better stabilized or repositioned in the active sites of the I346T and I346S 
CYP5A1 mutants. 
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FIG 4.4: MUTANT CYP5A1 AMINO ACID SEQUENCES AND PRIMERS USED FOR BLUNT-ENDED SITE-DIRECTED PCR MUTAGENESIS. The 
modified amino acid sequences are listed from residues 1-10 (top). The primers used for PCR mutagenesis are listed for each mutant (bottom). The 
forward primer introduces either a threonine or serine residue at position 346. The reverse primer creates a diagnostic NaeI RE site and places a 
silent mutation into Ala342. 
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Relative Production of MDA 
compared to WT 
Relative Production of TXB
2
 
compared to WT 
CYP5A1 Wild-type 100 ± 1.7% 100 ± 0.27% 
CYP5A1 Ile346Thr 107 ± 20.2% 239 ± 4.9% 
CYP5A1 Ile346Ser 96 ± 4.2% 161 ± 1.6% 
 
FIG 4.5: RELATIVE PRODUCT FORMATION OF CYP5A1 MUTANTS. Addition of the native substrate PGH2 to CYP5A1 in Nanodiscs results in the 
formation of TXA2, MDA and HHT. MDA was measured using UV-visible spectroscopy, while TXB2, (the hydrolysis product of TXA2) was 
measured using a standard ELISA kit. (Top) (A) Results for assays with CYP5A1-ND WT, I346T, and I346S performed are reported along with 
standard error. (B) Schematic showing the conversion of PGH2 into TXA2, MDA and HHT by CYP5A1-ND. The protein CYP5A1 (purple) is 
incorporated into the lipid bilayers (white) and these layers are surrounded by membrane scaffold protein (blue). (Bottom) Table showing the 
average product formation from Panel A with standard deviations. 
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FIG 4.6: SPECTRAL CHARACTERIZATION OF WILD-TYPE AND MUTANT CYP5A1-ND. Carbon monoxide bound difference spectra of (A) 
CYP5A1-ND WT, (B) the I346T mutant, and (C) the I346S mutant. 
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FIG 4.7: EQUILIBRIUM BINDING STUDIES OF CYP5A1-ND WITH SUBSTRATE ANALOGS. The binding of substrate analog U44069 to (A) 
CYP5A1-ND I346T and (B) CYP5A1-ND I346S showed an average Kd of binding of 5.0 ± 0.3 µM and 4.0 ± 1.8 µM for I346T and I346S, 
respectively. The binding of substrate analog U46619 to (C) CYP5A1-ND I346T and (D) CYP5A1-ND I346S showed an average Kd of binding of 
15 ± 3.0 µM and 2.9 ± 0.1 µM for I346T, and I346S, respectively. (Insets) Absorbance spectra of equilibrium binding of CYP5A1-ND with 
substrate analogs. 
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FIG 4.8: EQUILIBRIUM BINDING OF CYP5A1-ND WITH CYTOCHROME P450 REDUCTASE. The binding of CPR to CYP5A1-ND WT was 
determined by spectroscopic titration, performed in duplicate, with increasing concentrations of CPR ranging from 0.05 to 4.5 μM. The average Ks 
of binding was 0.36 ± 0.16 μM. CYP5A1 association with CPR was monitored by the difference spectrum between 390 nm and 417 nm. 
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FIG 4.9: HYDROGEN PEROXIDE FORMATION BY CPR WITH CYP5A1 MUTANTS. The levels of hydrogen peroxide formed by purified CPR alone 
and by CPR following co-incubation with WT and each mutant of and CYP5A1-ND. Assays were performed in triplicate. 
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FIG 4.10: ENERGY MINIMIZED MOE ACTIVE SITE MODELS. Full view of (A) CYP5A1 WT bound to PGH2 with the active site heme shown in 
red. Panels (B-D) show the PGH2-bound CYP5A1 active sites of the following: (B) Wild type with isoleucine in yellow, (C) I346T mutant with 
threonine in green, and (D) I346S mutant with serine in magenta. The protein is represented as blue ribbons. The endoperoxide oxygens bound at 
carbon positions C9 and C11 are displayed in red near the heme. Note, however, that the binding of PGH2 into the serine active site is different 
from the wild-type and I346T proteins, placing the oxygens at carbon positions C9 and C11 further away from the heme. 
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Average Distance from PGH2 
Carbon 9 Oxygen to Heme (Å) 
Average Distance from PGH2 
Carbon 11 Oxygen to Heme (Å) 
Average Distance of OH 
to Heme (Å) 
CYP5A1 
Wild-type 
6.66 ± 0.70 6.85 ± 1.26 ----- 
CYP5A1 
Ile346Thr 
5.68 ± 1.16 5.99 ± 1.60 5.60 ± 0.13 
CYP5A1 
Ile346Ser 
6.66 ± 0.73 7.10 ± 0.94 4.60 ± 0.11 
 
 
FIG 4.11: CALCULATED DISTANCES FROM ENERGY MINIMIZED MOLECULAR OPERATING ENVIRONMENT PGH2-BOUND CYP5A1 MODELS. 
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TABLE 4.1 PURIFICATION YIELDS OF HUMAN 
P450 5A1 AND POINT MUTANT CONSTRUCTS 
FROM 6L E. COLI MEMBRANE FRACTIONS 
  P450 (nmol) 
CYP5A1 WT 271.8 
CYP5A1 I346T 150.0 
CYP5A1 I346S 165.0 
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TABLE 4.2 SPECTRAL CHARACTERIZATION OF CYP5A1-NANODISCS AND MUTANTS. The 
average wavelength shift (λ) and dissociation constant values (Kd) with standard deviations 
were obtained from spectral titrations, performed in duplicate 
Spectral Characteristics of CYP5A1-ND 
 
WT I346T I346S 
Oxidized (nm) 417 417 419 
Reduced (nm) 412 412 413 
CO-bound (nm) 452 451 454 
Aver. λ Shift for 
U46619 (nm) 
3.0 ± 0.0* 4.0 ± 0.0 8.5 ± 0.7 
Aver. λ Shift for 
U44069 (nm) 
4.0 ± 0.0* 4.5 ± 0.7 5.5 ± 0.7 
U44069 K
d
 (μM) 6 ± 3.0* 5.0 ± 0.3 4.0 ± 1.8 
U46619 K
d
 (μM) 5 ± 4.0* 15 ± 3.0 2.9 ± 0.1 
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CHAPTER 5: FUTURE DIRECTIONS 
 
Solubilization mutants of CYP2J2 
 
Like other P450 enzymes, CYP2J2 is associated with the membrane in the endoplasmic 
reticulum primarily through a transmembrane helix at the N-terminus and secondarily through 
hydrophobic patches in the F-G loop region and in the A helix region of the protein. The 
decrease in solubility due to these hydrophobic regions makes it more difficult to produce 
crystals for structural determination via X-ray crystallography. As of 2015, at least twenty-five 
human P450s, including ten members of family 2, have been determined structurally, but this 
does not include any members of subfamily 2J (www.rcsb.org). It is our goal to increase the 
solubility of CYP2J2 sufficiently for crystallization without compromising the activity of the 
protein. 
 
Previously, we increased the solubility and expression of CY2J2 with modifications that 
included deleting 34 amino acids (CYP2J2-34) of the hydrophobic N-terminus (124). We found 
that this construct of the enzyme has similar activity and substrate specificity as compared to the 
full-length wild type; and in addition it retained the ability to associate with a membrane bilayer 
(data not shown). It is widely assumed that truncation of the hydrophobic N-terminus of a P450 
would not greatly affect the 3-D structure and virtually all crystals of CYPs are obtained from a 
truncated version of the protein (145). Therefore, in order to crystallize CYP2J2 it is important to 
increase solubility without affecting enzyme function. 
 
Our strategy was to focus on key residues predicted to associate with lipid bilayers from our 
simulations with the Orientations of Proteins in Membranes (OPM) database. We found that 
these residues were 48-54, 56-59, 61, 233, 235-236, and 238-245. We also looked for previous 
evidence of family 2 CYPs having their solubility increased by having changes made to residues 
other than the hydrophobic N-terminus. It was previously reported that CYP2D6 had increased 
solubility following mutation at L230 and L231 (57). In addition CYP2C9 had similar results 
with 7 F-G loop mutations (56) and CYP2C5 had increased solubility with 5 mutations in the F 
helix region (Fig 5.1) (146). We chose to base new CYP2J2 mutants on the CYP2D6 study, and 
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we found that the hydrophilic residues M237 and K238 of CYP2J2 align with L230 and L231 of 
CYP2D6. So that the mutants would be changes from hydrophobic to hydrophilic residues, the 
neighboring residues I236 and F239 of CYP2J2 were chosen for mutagenesis. Using the 
previously described blunt-ended inverse PCR methodology (Chapter 2), the mutants 34-
I236D, 34-F239H, and 34-I236D/F239H were made. 
 
The purpose of creating these mutants was to increase the solubility of CYP2J2. An indication 
that this was happening was that the percentage of CYP2J2 present in the soluble vs. the 
membrane fraction was affected by mutation in the following fashion: 34, 34-I236D, 34-
F239H, and 34-I236D/F239H had values for the soluble fraction of 39%, 47%, 51%, and 65%, 
respectively. This was confirmed by computer simulations of membrane insertion with 
Molecular Dynamics software and fluorescence-based Nanodisc experiments to detect 
membrane insertion; these studies showed that the point mutants all inserted less deeply than the 
wild-type protein (147). 
 
For any of the mutants to be useful for obtaining a 3-D structure it is important that they be 
shown to have activity close to that of wild-type. The assumption is that if the reaction with 
several substrates is unchanged, then the most critical regions of the protein such as the substrate 
access tunnels, the binding pocket, and the active site are likely to be nearly in their native state. 
Two enzyme assays were performed: the conversion of arachidonic acid (AA) to 
epoxyeicosatrienenoic acids (EETs) and the conversion of ebastine to hydroxyebastine (Fig 5.2). 
Results were analyzed with LC-MS/MS as previously described (39, 148). For the assay with 
AA, the four possible types of EETs were produced in a similar ratio for all constructs. The 34-
I236D which had an overall rate that was more than double. For the assay with ebastine, the 
hydroxyebastine was produced at a rate nearly 4 times higher by 34-I236D, but nearly 4 times 
lower by 34-F239H. Interestingly, the 34-I236D/F239H rate was nearly that of the wild-type 
for this assay, as well. The combination of the two results leads one to believe that the two 
mutants together might compensate for one another. Molecular Dynamics simulations show that 
these residues are likely to be in close proximity and therefore they may stabilize one another 
(147). 
 
84 
The ultimate goal for this project will be to collaborate with others who are experts in X-ray 
crystallography. Now that we have a more soluble version of the protein that maintains 
enzymatic activity similar to that of wild-type, 34-I236D/F239H, the next step is to proceed 
towards crystallizing CYP2J2. 
 
Key residues of CYP2J2 affecting fatty acid metabolism 
 
CYP2J2 is capable of metabolizing -3 and -6 fatty acids by epoxidation of double bonds and 
by hydroxylation of terminal carbons. We will further investigate the specificity of these 
reactions by analyzing the conversion of the 20-carbon -6 fatty acid AA to EETs by 
epoxidation and to HETEs by hydroxylation. A combination of sequence alignments and 
molecular modeling was used to select amino acid residues of CYP2J2 that might have an effect 
on the selectivity of the reactions with AA. Mutants were then produced or will be produced 
using previously described (Chapter 2) class-IIS inverse PCR methodology (Table 5.1). The 
overall rates of epoxidation to EETs and hydroxylation to HETEs have been or will be 
determined. The investigations that have been started can be divided into three broad categories: 
(1) mutations proximal to the heme, (2) active site mutations distal to the heme, and (3) binding 
pocket mutations distal to the heme. Proximal or distal mutations causing changes in factors such 
as electrostatics, hydrophobic environment, and protein conformation could change the midpoint 
redox potential of the heme (149). Mutations that change redox potential or access of water could 
affect the relative contribution to a reaction of the various steps in the P450 cycle, thus they 
would likely influence only overall hydroxylation to epoxidation ratios. Distal mutations that 
affect substrate orientation may change the regioselectivity of the products, thus changing ratios 
among the EETs and/or among the HETEs. 
 
Proximal mutations 
 
Mutations of CYP2J2 that are proximal to the heme could influence the midpoint redox potential 
of the heme, but would not be expected to affect substrate orientation since reactions take place 
on the opposite side of the heme. All P450s have an absolutely conserved cysteine that is ligated 
to the Fe of the heme from the proximal side; in CYP2J2 this residue is C448. An example of a 
85 
proximal side residue that has great influence on the activity of the heme is the highly conserved 
F441 of CYP2J2, which along with C448 is part of a highly conserved motif among CYPs, 
FXXGXXXCXG (4). A mutation in this position, F429H in CYP2B4, caused a major shift in the 
redox potential of the heme and in the activity of the enzyme. The effects were major because of 
the direct interaction of this residue with the cysteine thiolate and the heme.(150, 151). We have 
made two other more subtle mutations on the proximal side of the heme to potentially gain some 
insight into the different ratios of hydroxylation to epoxidation seen between the CYP2J2 
proteins of sheep and human. It has been established that the sheep enzyme has a greater amount 
of hydroxylation of arachidonic acid whereas the human enzyme has a greater amount of 
epoxidation; the regioselectivity among EETs and among HETEs is similar between the two 
species (17). Because the ratio of these two reactions could be due to differences in the redox 
potential of the two enzymes, we looked at our 3-D model to determine what amino acids were 
in close proximity, i.e., within 10 angstroms of the proximal side of the heme. Such residues 
might change the environment near the heme without directly interacting with the heme or C448. 
We then compared the primary sequence alignments of the human and sheep enzymes in search 
of residues that were not conserved. We focused on two positions with species differences in 
CYP2J2. The first residue is M439 in human, but is a leucine in sheep. A second residue is A447 
in human, but is a methionine in sheep. Essentially, a methionine and a small hydrophobic 
residue on the proximal side of the heme swap places between human and sheep. Consequently, 
we created the M439L mutant and the A447M mutant; in the future we may make the double 
mutant M439L/A447M (Fig 5.3). It will be interesting to see if any of these changes are 
significant enough to make the human enzyme act more like the sheep enzyme in terms of the 
hydroxylation to epoxidation ratio. The exact nature of subtle changes in electrostatics, 
hydrophobic environment, and protein conformation are difficult to predict, but such changes are 
definitely possible when a significant change in side chains is in such close proximity to the most 
highly conserved motif in CYPs. It is worth noting that position 447 is more centrally located 
between the two propionates of the heme than is position 439. We do not predict that either of 
these mutations would have an effect on regioselectivity since they would not directly affect 
substrate binding on the distal side. 
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Distal mutations 
 
Amino acids that are distal to the heme near the active site are defined here as residues within 7 
angstroms of the heme on the side where the reaction takes place, which is the side opposite the 
conserved cysteine ligated to the heme. Mutations in these residues may have an effect by 
affecting the position of water molecules, which are important for proton transfer via hydronium 
ions (8), or by affecting the positioning of substrate molecules such as AA. The most obvious 
candidate for mutagenesis is the highly conserved threonine residue located on the I-helix; in 
CYP2J2 this is T315. This residue is absolutely conserved among all family 2 members and in 
nearly all other CYPs (Fig 4.2). Many other CYPs have been mutated to alanine or valine at this 
position (105-109, 136). It may be expected that epoxidation and hydroxylation rates would 
always decrease without this key residue needed for hydrogen bonding with water molecules. 
However, in a key study (9) it was shown that upon mutation of this threonine to alanine 
CYP2B4 showed a decrease in hydroxylation and epoxidation rates, whereas CYP2E1 showed a 
decrease in hydroxylation and an increase in epoxidation rates. This phenomenon may be related 
to the fact that hydroxylation involves a reaction primarily with Compound I, which is formed 
after the transfer of two protons, but epoxidation may involve a reaction with Compound I or 
with the hydroperoxo intermediate, the previous step in the pathway requiring a transfer of only 
one proton (Fig 5.4). A possible explanation of the difference between these two proteins is that 
the CYP2B4 mutant has significant inhibition of both proton transfer steps, but the CYP2E1 
mutant inhibits mainly the second proton transfer step. This would allow CYP2E1 to increase the 
rate of epoxidation due to a higher level of the hydroperoxo intermediate (Fig 5.4). Based on 
these results our approach was to create both a T315A and a T315V mutant. These hydrophobic 
amino acids do not exceed the size of the native threonine and may result in a decreased capacity 
to hydrogen bond water molecules at the active site. We tested these mutants by analyzing the 
conversion of AA to EETs and HETEs. Our preliminary data (Fig 5.5) showed that the CYP2J2 
T315A mutant was much like the CYP2E1 mutant in that epoxidation products (EETs) increased 
while hydroxylation products (HETEs) decreased relative to wild-type. This data also showed 
that the CYP2J2 T315V mutant was much like the CYP2B4 mutant in that both EETs and 
HETEs decreased relative to wild-type. Our initial theory is that the two additional methyl 
groups present in valine versus alanine make it more difficult for water molecules to position 
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properly in the active site. This could cause the first proton transfer step to be inhibited in the 
T315V mutant, whereas only the second proton transfer step was inhibited in the T315A mutant. 
Consistent with the idea that only the overall hydroxylation to epoxidation ratio is being affected, 
the ratios among the EETs and among the HETEs remain similar. The exception to this is the 
ratio of 5,6-EET to the other EETs, however quantification of 5,6-EET is much less reliable 
using current methodology. These product ratios indicate that orientation of substrate is not being 
affected. It is possible that disruption of the transfer of one or both protons by these mutants is 
affecting the ratio of the active intermediates and thus the ratio of hydroxylation to epoxidation. 
 
There are other key residues near the active site of CYP2J2 that may affect the regioselectivity 
and/or the hydroxylation to epoxidation ratio. In our 3-D model we have identified I376 and 
V380 as distal residues that are positioned directly above the heme; of the two, I376 is closer to 
T315.  These residues are also along a predicted pathway for proton transfer between T315 and a 
highly conserved arginine R382, which corresponds to CYP3A4 R375, a residue thought to be 
involved in solvent gating (8). Other residues near position 315 have been predicted to play a 
role in proton transfer in CYP2D6 (136). In an alignment with CYP2B4 and CYP2E1, CYP2B4 
has the same residues at these two positions, but CYP2E1 has a smaller residue, V363, in the 
position of the CYP2J2 I376, and has a larger residue, L367, in the position of the CYP2J2 V380 
(Fig 5.6). In a study of cytochrome c oxidase others have predicted that along a proton transfer 
pathway a valine mutant may be more accommodating than the larger side chain of an isoleucine 
mutant for water clusters, thus making proton transfer easier (152). Similarly, we predict that 
larger residues in these positions might decrease proton transfer rates and therefore affect rates of 
product formation. However, in a study involving CYP2E1 mutants V363L and L367V, there 
was minimal change in overall product formation but rather there were small changes in both 
hydroxylation to epoxidation ratios and in the regioselectivity among the EETs and among the 
HETEs (Fig 5.7) (153). This difference in regioselectivity indicates that the mutations were 
affecting the orientation of substrate; the possible differences due to proton transfer rates were 
not considered. To further investigate these positions in CYP2J2 we have successfully made 
mutants I376V and V380L. We will be making comparisons by looking at these two positions in 
another family 2 protein, CYP2J2. In addition to quantifiying 2 HETEs we will also be able to 
quantify all four EETs, whereas the previous study could only separate 14,15-EET from the other 
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three EETs (153). We may also make double mutants consisting of I376V, V380L, and/or 
T315A/T315V to see the combined effect of these mutations.  
 
To further test whether proton transfer is being affected we propose to carry out kinetic solvent 
isotope effect (KSIE) experiments on these mutants near the active site (154, 155). In these 
experiments the use of heavy water, or deuterium, will slow down the rate of proton transfer. 
Since the products formed are relying on the transfer of one or two protons, the relative effect of 
the heavy water will be greater as the number of proton transfers increases. In conjunction with 
these experiments we may also use Molecular Dynamics simulations to predict in our various 
mutants proton transfer via a wire of water molecules (156). Our T315 mutants are good 
candidates for such experiments since the hydroxylation to epoxidation ratio is changed and 
since ratios among EETs and among HETEs appear to remain constant, thus indicating changes 
in substrate orientation are unlikely. The interpretation of results from the mutation of residues 
376 and 380 may be more difficult to decipher since it is reasonable that there may be effects 
from both proton transfer and from substrate orientation. 
 
In the future we hope to also generate mutants to elucidate the role of various residues in the 
CYP2J2 binding pocket. We have used MOE with our hybrid model to identify those residues 
that are likely to be in the cavity between the protein surface and the active site. We have 
compared these residues with other family 2 proteins using a primary sequence alignment. Two 
obvious candidates among these residues are M116 and R117 because all other family 2 proteins 
have smaller, usually hydrophobic, residues at these positions. In addition, our initial Molecular 
Dynamics studies (Javier Baylon, unpublished data) predict that R117 may have a greater 
affinity for arachidonic acid when it is positioned for epoxidation rather than hydroxylation. A 
first step would be to create both M116V and R117V mutants to see if this affects the 
hydroxylation to epoxidation ratio and/or the regioselectivity among EETs or HETEs. 
Interestingly, there is a naturally occurring polymorphism CYP2J2*10, which is a P115L mutant 
(5). It is plausible that the mutation of a proline, known for its ability to affect secondary 
structure, in such close proximity to M116 and R117 could have an effect on substrate binding, 
so we wish to generate and test this P115L mutant also. 
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Regarding products of CYP2J2, hydroxylation to epoxidation ratios and the ratios of various 
regioisomers can affect many cellular processes. Therefore, the results of these studies will be 
informative as we focus on amino acids that differ among that differ among various family 2 
CYPs, that differ among CYP2J2 in various species, and that differ due to various 
polymorphisms of CYP2J2 in humans. 
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Chapter Figures 
 
 
 
 
 
 
 
 
 
 
FIG 5.1: PRIMARY SEQUENCE ALIGNMENT OF CYP2J2, CYP2D6, CYP2C5, AND CYP2C9. An alignment of amino acids from CYP2J2, 
CYP2D6, CYP2C5, and CYP2C9 was made using CLUSTALW. Ile236 and Phe239 of CYP2J2 from the F-G loop region are highlighted 
(yellow). Previously mutated CYP2D6 leucine residues from the F-G loop region are highlighted (yellow) (57). Previously mutated residues of 
CYP2C5 (rabbit) (146) and CYP2C9 (56) from their F helix and F-G loop regions are highlighted (yellow). 
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FIG 5.2: METABOLISM ASSAYS FOR CYP2J2 SOLUBILIZATION MUTANTS. For wild-type CYP2J2 (34) and three mutants (A) the rate of 
conversion of ebastine to hydroxyebastine was determined, and (B) the rate of conversion of arachidonic acid to four EETs was determined. Figure 
prepared by Daniel McDougle. 
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FIG 5.3: PRIMARY SEQUENCE ALIGNMENT OF CYP2J2 FROM SHEEP AND HUMAN. An alignment of regions of two CYP2J2 proteins was made 
using CLUSTALW. Cys448 of human CYP2J2 is highlighted (green) along with the corresponding cysteine residue in sheep. Met439 and Ala437 
of human CYP2J2 are highlighted (yellow) along with the corresponding leucine and methionine residues of sheep CYP2J2. 
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FIG 5.4: PROPOSED REACTIVE INTERMEDIATES OF P450S. An illustration of proposed reactive intermediates of the P450 reaction cycle. From 
arachidonic acid the hydroperoxo intermediate would be more likely to form EETs by epoxidation and the oxenoid intermediate (Compound I) 
would be more likely to form HETEs by hydroxylation. Adapted with permission from (9) copyright 1998 National Academy of Sciences, USA. 
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FIG 5.5: EPOXIDATION AND HYDROXYLATION RATES FOR CYP2J2 THREONINE MUTANTS. Data for metabolite production from WT (34), 
T315A, and T315V mutants for CYP2J2 following incubation with arachidonic acid for 30 minutes. Levels of production for four EETs and for 
two HETEs are indicated. 
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FIG 5.6: PRIMARY SEQUENCE ALIGNMENT OF CYP2B4, CYP2E1 AND CYP2J2. An alignment of 120 amino acids from CYP2B4, CYP2E1, and 
CYP2J2 was made using CLUSTALW. Thr315 of CYP2J2 is highlighted (purple) along with the corresponding threonine residues of the other 
proteins. Ile376 and Val380 of CYP2J2 are highlighted (yellow) along with the corresponding isoleucine, valine, and leucine residues of the other 
proteins. 
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FIG 5.7: ARACHIDONIC ACID METABOLISM BY CYP2E1 MUTANTS. Data is shown for arachidonic acid metabolism to HETEs and EETs by wild-
type CYP2E1 (2E1dH) and several mutants. V363L is a mutant in the same position as CYP2J2 I376V and L367V is a mutant in the same position 
as CYP2J2 V380L. Adapted with permission from (153). 
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Primer name 
(mutation-direction) 
Primer sequence 
 
M439L-For     
M439L-Rev  
A447M-For  
A447M-Rev  
T315A-For  
T315A-Rev  
T315V-For  
T315V-Rev  
I376V-For  
I376V-Rev  
V380L-For  
V380L-Rev  
 
5'- GA TAA GGC TCT TCT TTC TGC CTT TCT CAA TAG GAA AGC GGG CAT -3' 
5'- TA TTG AGC TCT TCA GAA AGG CTT CCC TTT TCT TAA ACT GTC CA -3' 
5'- CA GTA GGC TCT TCG ATG TGC CTC GGA GAA CAG TTG GCC AGG AC -3' 
5'- TG ATC TGC TCT TCA CAT CCG CTT TCC TAT TGA GAA AGG CAT AA -3' 
5’- TT GAC GGC TCT TCG GCA ACT TCC ACA ACT CTG CGA TGG G -3' 
5’- AG AAT TGC TCT TCT TGC CTC GGT TCC GGC AAA GAA GAG GTC C -3' 
5’- TT GAC GGC TCT TCG GTA ACT TCC ACA ACT CTG CGA TGG G -3' 
5’- AG AAT TGC TCT TCT TAC CTC GGT TCC GGC AAA GAA GAG GTC C -3' 
5'- GA TAG GGC TCT TCC GTC CCC CTG AAC GTT CCC AGG GAA GTG -3' 
5'- GG TTC GGC TCT TCG GAC GAT GTT GCC CAT TCT CTG CAC C -3' 
5'- TC TTC CGC TCT TCC CTT CCC AGG GAA GTG ACA GTT GAT ACC A -3' 
5'- GT CAC TGC TCT TCG AAG GTT CAG GGG GAT GAT GTT GCC CAT TCT C -3' 
 
 
TABLE 5.1: CYP2J2 MUTAGENESIS PRIMERS USED FOR CLASS-IIS INVERSE PCR. Two primers each, forward (For) and reverse (Rev), were 
designed for six CYP2J2 mutants. Proximal mutants created were M439L and A447M, and distal mutants created were T315A, T315V, I376V, 
and V380L. The SapI recognition sequence, 5’-GCTCTTC-3’, and the 3-nucleotide region that would be the site of the 5’ cohesive overhang are 
underlined; the mutagenic sequence is marked in bold. Note that the cohesive ends of each primer pair will be complementary. 
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